

Existing Chemical Hazard Assessment Report



Australian Government
Department of Health and Ageing
NICNAS

Diethylhexyl Phthalate

June 2008

© Commonwealth of Australia 2008

This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining this notice) for your personal, non-commercial use or use within your organisation. Apart from any use as permitted under the Copyright Act 1968, all other rights are reserved. Requests and inquiries concerning reproduction and rights should be addressed to Commonwealth Copyright Administration, Attorney General's Department, Robert Garran Offices, National Circuit, Barton ACT 2600 or posted at <http://www.ag.gov.au/cca>

Preface

This report was compiled by the National Industrial Chemicals Notification and Assessment Scheme (NICNAS). This Scheme was established by the *Industrial Chemicals (Notification and Assessment) Act 1989* (Cwlth) (the Act), which came into operation on 17 July 1990.

The principal aim of NICNAS is to aid in the protection of people at work, the public and the environment from the harmful effects of industrial chemicals.

NICNAS assessments are carried out in conjunction with the Department of Environment and Heritage, which carry out the environmental assessment for NICNAS. NICNAS has two major programs: the assessment of the health and environmental effects of new industrial chemicals prior to importation or manufacture; and the other focussing on the assessment of chemicals already in use in Australia in response to specific concerns about their health/or environmental effects.

There is an established mechanism within NICNAS for prioritising and assessing the many thousands of existing chemicals in use in Australia.

For the purposes of Section 78(1) of the Act, copies of assessment reports for New and Existing Chemical assessments are freely available from the web (www.nicnas.gov.au). Summary Reports are published in the *Commonwealth Chemical Gazette* (<http://www.nicnas.gov.au/publications/#gazette>), and are available to the public on line at www.nicnas.gov.au.

Copies of this report and other NICNAS reports are available on the NICNAS website. Hardcopies are available from NICNAS at the following address:

GPO Box 58
Sydney NSW 2001
AUSTRALIA
Attention: Office Manager
Tel: +61 (02) 8577 8800
Freecall: 1800 638 528
Fax: +61 (02) 8577 8888
Email: info@nicnas.gov.au

Other information about NICNAS (also available on request) includes:

- NICNAS Annual Reports.
- NICNAS Service Charter.
- Brochure on NICNAS Registration.

More information on NICNAS can be found at the NICNAS web site:

<http://www.nicnas.gov.au>

Overview

This review of diethylhexyl phthalate (DEHP) is a health hazard assessment only. For this assessment, key reviews on DEHP prepared by the European Chemicals Bureau, the US Centre for the Evaluation of Risks to Human Reproduction and the US Agency for Toxic Substances and Disease Registry were consulted. Information from these reviews was supplemented with recent literature surveys conducted up to September 2006.

DEHP is the one of the most extensively used phthalates worldwide. In the USA, approximately 97% of DEHP is used as a plasticiser in PVC. DEHP-containing PVC is used in a variety of consumer products such as toys, automotive components, furniture, shoes, outdoor wear and building materials. DEHP is also used as an ingredient in cosmetics and medical products. Current EU legislation restricts the use of DEHP in toys and childcare articles, and prohibits its use in cosmetics.

In Australia, DEHP is used in flooring, waterproofing materials, cable sheathing/insulation, PVC labels, surface repair resin moulds, epoxy and polyurethane products, rubber components in automotive brake assemblies and hot melt adhesives for automotive assembly and repair. DEHP is also used in fragrance bases for perfumery and cosmetic products. Some businesses note phasing out of the chemical in these latter applications following the ban on cosmetics use in the EU.

Structurally, phthalate esters are characterized by a diester structure consisting of a benzenedicarboxylic acid head group linked to two ester side chains. DEHP possesses 2 branched ester side chains each with a 6 carbon backbone (C6).

Toxicity data for DEHP are available for most health endpoints. For endpoints with incomplete data, information from structurally similar phthalates, where available, was used to extrapolate potential toxicity. Relevant read-across information was obtained from other NICNAS hazard assessment reports for phthalates and the NICNAS Phthalates Hazard Compendium, which contains a comparative analysis of toxicity endpoints across 24 ortho-phthalates, including DEHP.

DEHP is rapidly absorbed following oral administration. In contrast, the absorption of DEHP via the skin is low. The liver, kidney, testes and blood are the main sites of distribution following orally administered DEHP. There is no evidence of accumulation in animal tissues. DEHP and metabolites are excreted in the urine and faeces. A recent human study noted that 75% of orally administered DEHP was eliminated as metabolites via urine within 2 days

In experimental animals, DEHP exhibits low acute oral, dermal and inhalation toxicity. DEHP induced minimal skin and eye irritation in animals and did not induce skin irritation in human volunteers. Data are insufficient to determine the respiratory irritant potential of DEHP. DEHP was not a skin sensitiser in animals and limited data indicate no sensitisation reactions in humans. Data are insufficient to determine the respiratory sensitization potential of DEHP.

Repeat dose effects of DEHP have been evaluated in a number of animal species by several routes of exposure. The most pronounced findings were effects on the liver, testes and kidneys. For liver and kidney toxicity (increases in serum albumin, absolute and/or relative liver and kidney weights and hepatic peroxisome proliferation) a LOAEL was established from a well-conducted 104-week rat dietary study at 146.6 mg/kg bw/d. The NOAEL was

28.9 mg/kg bw/d. For testicular effects, a LOAEL was established at 37.6 mg/kg bw/d based on an increased incidence of Sertoli cell vacuolation in a 13-week rat dietary study. The NOAEL was 3.7 mg/kg bw/d.

Studies of DEHP in monkeys failed to elicit the liver, kidney or testicular effects seen in rodents. Given the minimal effects with DEHP in non-human primates, a similar low sensitivity of humans to the peroxisome proliferative effects of DEHP is expected.

On a weight-of-evidence basis, DEHP is considered to be non-genotoxic. In carcinogenicity studies, DEHP showed positive transforming potential in some but not all mammalian cell transformation assays in vitro. In vivo, DEHP caused an increase in the incidence of liver tumours with a dose-response relationship in rats and mice of both sexes. DEHP-induced hepatocellular carcinomas are unlikely to be of relevance to humans since the hepatotoxic effects of DEHP are associated with peroxisome proliferation to which humans appear less sensitive.

The critical effects for DEHP are considered to be reproductive and developmental effects in males. Testicular toxicity appears to be the most sensitive toxicity endpoint but is significantly influenced by the age at exposure. Developing and prepubertal rats have been found to be much more sensitive to exposure to DEHP than adults. The younger animals responded to a much lower dose or produced a more serious lesion with a comparable dose on a mg/kg bw/d basis.

For effects on fertility, the NOAEL was 14 mg/kg bw/d based on a study in a continuous breeding study in mice. The LOAEL in this study was 140 mg/kg bw/d, not necessarily linked to male infertility as both sexes were exposed to DEHP in the diet. A crossover study at the highest dose indicated both males and females had reduced fertility.

A number of key studies exposed animals during gestation and/or early postnatal life. A NOAEL of 4.8 mg/kg bw/d and a LOAEL of 14 mg/kg bw/d was established for developmental toxicity based on testicular effects.

Table of Contents

| | |
|---|------|
| PREFACE | iii |
| OVERVIEW | iv |
| ACRONYMS AND ABBREVIATIONS | viii |
| 1. INTRODUCTION | 1 |
| 2. IDENTITY | 2 |
| 2.1 Identification of the substance | 2 |
| 2.2 Physico-chemical properties | 2 |
| 3. USES | 3 |
| 4. HUMAN HEALTH HAZARDS | 4 |
| 4.1 Toxicokinetics | 4 |
| 4.2 Acute toxicity | 6 |
| 4.3 Irritation | 7 |
| 4.3.1 Skin irritation | 7 |
| 4.3.2 Eye irritation | 8 |
| 4.3.3 Respiratory irritation | 8 |
| 4.4 Sensitisation | 9 |
| 4.4.1 Skin sensitisation | 9 |
| 4.4.2 Respiratory sensitisation | 9 |
| 4.5 Repeated dose toxicity | 10 |
| 4.6 Genetic toxicity | 15 |
| 4.7 Carcinogenicity | 15 |
| 4.8 Reproductive toxicity | 18 |
| 4.8.1 Human studies | 18 |
| 4.8.2 Repeat dose toxicity studies | 20 |
| 4.8.3 Continuous breeding reproductive toxicity studies | 24 |
| 4.8.4 Two- and three-generation reproductive toxicity studies | 24 |
| 4.8.5 Developmental/postnatal toxicity studies | 25 |
| 4.8.6 Prenatal developmental toxicity studies | 27 |
| 4.8.7 Mode of action | 29 |
| 5. HAZARD CHARACTERISATION | 32 |

| | |
|---|----|
| 6. HUMAN HEALTH HAZARD SUMMARY TABLE | 35 |
| REFERENCES | 37 |
| APPENDIX 1 - ROBUST STUDY SUMMARIES | 49 |
| APPENDIX 2 – EFFECTS OF DEHP FOLLOWING REPEATED ORAL, INHALATION AND PARENTERAL ADMINISTRATION | 53 |
| APPENDIX 3 – KEY REPRODUCTION STUDIES WITH DEHP IN LABORATORY ANIMALS | 63 |

Acronyms and Abbreviations

| | |
|-------|--|
| 2-EH | 2-ethylhexanol |
| AGD | anogenital distance |
| AGI | anogenital index |
| AR | androgen receptor |
| ATSDR | Agency for Toxic Substances and Disease Registry (US) |
| BBP | butylbenzyl phthalate |
| bw | body weight |
| C | Celsius |
| CAS | Chemical Abstracts Service |
| CERHR | Centre for the Evaluation of Risks to Human Reproduction |
| CHO | Chinese hamster ovary |
| d | day |
| DBP | dibutyl phthalate |
| DEHP | diethylhexyl phthalate |
| DEP | diethyl phthalate |
| DINP | diisononyl phthalate |
| DMP | dimethyl phthalate |
| DNA | deoxyribonucleic acid |
| DOP | dioctyl phthalate |
| DOTP | dioctyl terephthalate |
| ECB | European Chemicals Bureau |
| ECMO | extracorporeal membrane oxygenation |
| ER | oestrogen receptor |
| EU | European Union |
| f | female |
| F0 | parental generation |
| F1 | filial 1 (first generation) |
| F2 | filial 2 (second generation) |
| FDA | Food and Drug Administration |
| FSH | follicle-stimulating hormone |
| g | gram |
| GD | gestation day |
| GIT | gastro-intestinal tract |

| | |
|--------|--|
| GLP | good laboratory practice |
| h | hour |
| IgE | immunoglobulin E |
| ip | intraperitoneal |
| kg | kilogram |
| kPa | kilopascals |
| L | litre |
| LC50 | median lethal concentration |
| LD50 | median lethal dose |
| LH | luteinizing hormone |
| LOAEL | lowest-observed-adverse-effect level |
| m | male |
| MBP | mono-n-butyl phthalate |
| MBzP | monobenzyl phthalate |
| MCL | mononuclear cell leukaemia |
| MEHP | monoethylhexyl phthalate |
| MEP | monoethyl phthalate |
| mg | milligram |
| MiBP | monoisobutyl phthalate |
| MiNP | mono-isononyl phthalate |
| mL | millilitre |
| mMP | mono-methyl phthalate |
| NICNAS | National Industrial Chemicals Notification and Assessment Scheme |
| NOAEL | no-observed-adverse-effect level |
| NTP | National Toxicology Program |
| OECD | Organisation for Economic Cooperation and Development |
| PND | post-natal day |
| ppm | parts per million |
| PVC | polyvinyl chloride |
| SCHER | Scientific Committee on Health and Environmental Risks (EU) |
| SHBG | sex-hormone binding globulin |
| w/v | weight per volume |
| w/w | weight per weight |
| μ | micro |

1. Introduction

This review of diethylhexyl phthalate (DEHP) is a health hazard assessment only. For this assessment, key reviews on DEHP prepared by the European Chemicals Bureau (ECB, 2006), the Centre for the Evaluation of Risks to Human Reproduction (CERHR, 2005) and the Agency for Toxic Substances and Disease Registry (ATSDR, 2002) were consulted. Information from these reviews was supplemented with relevant studies from more recent literature surveys conducted up to September 2006.

Information on Australian uses was compiled from data supplied by industry in 2004 and 2006.


References not marked with an asterisk were examined for the purposes of this assessment. References not examined but quoted from the key reviews as secondary citations are also noted in this assessment and marked with an asterisk.

Hazard information from this assessment is published also in the form of a hazard compendium providing a comparative analysis of key toxicity endpoints for 24 *ortho*-phthalate esters (NICNAS, 2008).

2. Identity

2.1 Identification of the substance

CAS Number: 117-81-7
 Chemical Name: 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester
 Common Name: Diethylhexyl phthalate (DEHP)
 Molecular Formula: $C_{24}H_{38}O_4$
 Structural Formula:



R =
 Molecular Weight: 390.56
 Synonyms: 1,2-Benzenedicarboxylic acid, bis(2-ethylhexylester); Phthalic acid, bis(2-ethylhexyl)ester; Bis(2-ethylhexyl) 1,2-benzenedicarboxylate; Bis(2-ethylhexyl) o-phthalate; Bis(2-ethylhexyl)phthalate; Di-2-ethylhexyl-phthalate; Ethylhexyl phthalate; Dioctyl Phthalate; Di(isooctyl) phthalate; Octyl phthalate; DOP
 Purity/Impurities/Additives: Purity: $\geq 99.7\%$ w/w
 Impurities: other phthalates
 Additives: none

2.2 Physico-chemical properties

Table 1: Summary of physico-chemical properties

| Property | Value |
|---|---|
| Physical state | Oily liquid |
| Melting point | -47°C |
| Boiling point | 384°C |
| Density | 984 kg/m ³ (20°C) |
| Vapour pressure | 1.33 x 10 ⁻⁸ kPa (25°C) |
| Water solubility | 4.1 x 10 ⁻⁵ g/L (25°C) |
| Partition coefficient n-octanol/water (log Kow) | 7.50 |
| Henry's law constant | 1.71 x 10 ⁻⁵ atm.m ³ /mole (25°C) |
| Flash point | 196°C |

Source: ATSDR (2002)

3. Uses

DEHP is the one of the most extensively used phthalates worldwide. In the USA up to 2002, approximately 97% of DEHP was used as a plasticiser in PVC (ATSDR, 2002). In the European Union (EU) up to 2006, DEHP use represented around half of the total volume of phthalates used as plasticisers (ECB, 2006). DEHP-containing PVC is used in a variety of consumer products e.g. toys, automotive components, furniture, shoes and boots, outdoor and rainwear, building material such as flooring, cables, profiles and roofs. DEHP is also used as ingredient in cosmetics and medical products like blood bags, dialysis equipment. Current EU legislation restricts the use of DEHP in toys and childcare articles, and prohibits its use in cosmetics.

In Australia, DEHP is used in flooring, waterproofing materials, cable sheathing/insulation, PVC labels, surface repair resin moulds, epoxy and polyurethane products, rubber components in automotive brake assemblies and hot melt adhesives for automotive assembly and repair. The chemical is also used in fragrance bases for perfumery and cosmetic products. Some businesses note phasing out of the chemical in these latter applications following the ban on cosmetics use in the EU.

4. Human Health Hazards

4.1 Toxicokinetics

Previous evaluations

The toxicokinetics of DEHP has been reviewed extensively. Toxicokinetic studies in experimental animals have been performed for the oral, inhalation, dermal and parenteral routes of exposure with the majority of toxicokinetic studies performed in rats by the oral route. There are a limited number of studies on the toxicokinetics of DEHP in humans. The following information is sourced from ECB (2006) and ATSDR (2002).

Oral

The first step in the absorption and metabolism of DEHP is hydrolysis by lipases to monoethylhexyl phthalate (MEHP) and 2-ethylhexanol (2-EH). Lipases are found in all tissues (intestinal mucosa, liver, kidney, lungs, skin, pancreas and adipose tissues) but especially in the pancreas (Albro, 1986*), correlating with the particularly rapid metabolism of DEHP in the intestine. Whereas unhydrolyzed DEHP can be absorbed, absorption in the intestine is increased following hydrolysis to MEHP. The extent of absorption in rats, non-human primates and humans is up to approximately 50% for doses up to 200 mg/kg bw. At higher doses, absorption in non-human primates is dose-limited, in contrast to rodents (Albro et al., 1982*; Rhodes et al., 1983*). This species difference is reflected in differences in the activity of DEHP-metabolizing enzymes. The rate of MEHP formation from DEHP substrate differed by up to 357-fold among species, being highest in CD-1 mice, next in Sprague–Dawley rats and lowest in marmosets in all organs measured (liver, lungs, kidneys, and small intestine) (Ito et al., 2005).

Radiolabel studies show the liver, kidney, testes and blood as the main sites of distribution following orally administered DEHP in rats and monkeys (Rhodes et al., 1986*). There is no evidence of accumulation of DEHP or metabolites in animal tissues.

Metabolic pathways for DEHP involve a number of reactions. Following esteratic or hydrolytic cleavage of DEHP resulting in the formation of MEHP and 2-EH, MEHP is further metabolised via oxidative reactions resulting in the formation of numerous metabolites and a small amount of phthalic acid. Some of these oxidized derivatives are then conjugated with glucuronic acid prior to urinary excretion (Albro, 1986*, Astill, 1989*). The phthalic acid remains undegraded. Oxidation of 2-EH primarily yields 2-ethylhexanoic acid and several keto acid derivatives, which are also excreted in the urine.

Orally administered DEHP results in excretion of metabolites and minimal quantities of the parent compound predominantly via urine and faeces. In rats, excretion following low administered doses of DEHP occurs mostly via the urine, whereas in monkeys, excretion of similar doses occurs mostly via faeces. A recent human study noted that most (75%) of orally administered DEHP was eliminated as metabolites via urine within 2 days (Koch et al., 2005). In rats and mice, elimination is rapid with 85%-90% of a dose of radiolabelled DEHP being excreted via urine and faeces in the

first 24 hours. In monkeys, the 24 hour excretion rate was lower at 50%-80% (Astill, 1989*).

Limited human data from autopsies have indicated the presence of DEHP in adipose tissues (EPA 1989). However, it is suggested that this may be an artifact from contamination of biological samples during tissue processing.

Dermal

The absorption of DEHP via the skin has been reported to be low. No human in vivo dermal studies were found. However, Barber et al. (1992*) and Scott et al. (1987) compared in vitro absorption of DEHP through rat and human skin and found that permeability to DEHP was considerably greater for rat skin compared to human skin.

Dermal absorption was low in two studies conducted in rats (Melnick et al., 1987*; Elsisi et al., 1989). In these studies, 95% or 86% of the applied dose remained at the site of application after 5 or 7 days, respectively. Several studies in different species calculated the cumulative amount detected in excreta and tissues following dermal exposure: excluding the dosed skin, 6.5% in rat (Elsisi et al., 1989), 9% in rat (Melnick et al., 1987*), 26% in guinea pig (Ng et al., 1992*) and including the skin bound dose 9.7%-18.9% in guinea pig (Chu et al., 1996*). One study determined the percutaneous absorption rate for DEHP in PVC applied to rat skin to be 0.24 $\mu\text{g}/\text{cm}^2/\text{h}$ (Deisinger et al., 1998*).

Inhalation

Absorption of DEHP occurs via the respiratory tract but quantitative data following inhalation exposure of animals or humans have not been published. In rats exposed to an aerosol of radioactively labeled DEHP, the major route of elimination was the urine (General Motors, 1982a*, b*).

Case studies of patients and workers have been published indicating absorption of DEHP through the lungs. DEHP is absorbed by infants undergoing respiratory therapy with plasticised medical devices (Roth et al., 1988*). MEHP and three other main metabolites were identified from workers exposed to DEHP by inhalation in several studies (Liss et al., 1985*; Dirven et al., 1993a*, b*). Considerable human inter-individual variations in percentages of detected unmetabolised MEHP were reported.

Parenteral

DEHP exposures through the parenteral route bypass intestinal lipases, so the amounts of intact DEHP in organs and tissues would be expected to be higher with this exposure route. This is evident in data from human studies of exchange transfusions and haemodialysis where initially there is more DEHP than MEHP in the blood (Pollack et al., 1985a*, b*; Sjoberg et al., 1985a*). DEHP levels then decline rapidly with a half-life of 10 hours (Sjoberg et al., 1985a*) and MEHP levels increase until the time-averaged concentrations are roughly equal (Pollack et al., 1985b*).

Similar results were seen in animal studies. Following arterial injection, DEHP was rapidly cleared from the blood (half-life of 15 hours) (Pollack et al., 1985a*). In mice intravenously injected with labelled DEHP, radioactivity rapidly accumulated in the gall bladder, intestine, urinary bladder, liver, kidney and brown fat (Lindgren et al.,

1982*). Prolonged high levels in gall bladder and intestine after 24 hours suggest that secretion by the liver via bile is a major elimination route in mice. Following intravenous administration to marmosets, approximately 40% of the dose was excreted in urine and approximately 20% in the faeces (cumulative excretion) (Rhodes et al., 1983*). Around 28% remained in the lungs 7 days after administration with minimal levels in other tissues. Residual lung activity was postulated by these authors as reflecting insoluble emulsion entrapped within alveolar capillaries (Rhodes et al., 1986*).

Data not reported in previous evaluations

No data.

Conclusion

DEHP is rapidly absorbed from the gastrointestinal tract following oral administration. In contrast, absorption of DEHP via the skin is low. Case studies of patients and workers indicate absorption of DEHP via inhalation and the parenteral route. The extent of absorption of oral doses up to 200 mg/kg bw/d in rats, primates and humans is up to approximately 50%. Studies in rats and monkeys show the liver, kidney, testes and blood as the main sites of distribution following orally administered DEHP. However, DEHP and metabolites do not to accumulate in tissues.

The first metabolic step is the hydrolysis of DEHP to MEHP and 2-EH by tissue lipases. MEHP is further metabolised via oxidative reactions resulting in the formation of numerous metabolites and a small amount of phthalic acid. Elimination of metabolites and minimal quantities of the parent DEHP occurs mostly via urine and faeces. A recent human study noted that 75% of orally administered DEHP was eliminated as metabolites via urine within two days.

4.2 Acute toxicity

Previous evaluations

The acute toxicity of a single dose of DEHP has been evaluated in a number of species using oral, dermal, inhalation and intravenous routes of administration. LD50 values derived from these studies are shown in the Table 2

Human studies

Shaffer et al. (1945*) reported two adult male subjects who swallowed DEHP as single doses of 5 g and 10 g. No symptoms resulted from the 5 g dose while the ingestion of 10 g caused mild gastric disturbances and “moderate catharsis”. Assuming 70 kg body weight, this equates to a dose of 140 mg/kg.

Data not reported in previous evaluations

No data.

Conclusion

DEHP has low acute oral, dermal and inhalation toxicity. Intravenous and intraperitoneal administration of DEHP results in higher acute toxicity than oral or dermal administration.

Table 2 – Acute animal toxicity studies

| Study Type | Species | Results | References |
|------------------|------------|-----------------|--|
| (LD50/LC50) | | | |
| Oral | Rat | 30600 mg/kg bw | Shibko & Blumenthal, 1973 |
| | Rat | >20000 mg/kg bw | NTP, 1982* |
| | Rat | >40000 mg/kg bw | Nuodex, 1981a* |
| | Mouse | >20000 mg/kg bw | NTP, 1982* |
| | Mouse | >9860 mg/kg bw | Nuodex, 1981b* |
| | Guinea pig | 26000 mg/kg bw | Krauskop, 1973* |
| | Rabbit | 34000 mg/kg bw | Shaffer et al., 1945* |
| Dermal | Rabbit | 24750 mg/kg bw | ATSDR, 2002 |
| Inhalation (4 h) | Rat | >10.62 mg/L | Hüls, 1981* |
| Intravenous | Rat | 250 mg/kg bw | Schmidt et al., 1975*; Rubin & Chang, 1978* |
| | Mouse | 1060 mg/kg bw | Health Canada, 2002 |
| Intraperitoneal | Rat | 5675 mg/kg bw | Shaffer et al., 1945* |
| | Mouse | 2800 mg/kg bw | Lawrence et al., 1975*; Woodward et al., 1986* |

Source: ECB (2006)

4.3 Irritation

4.3.1 Skin irritation

Previous evaluations

In a human study, an unidentified quantity of DEHP applied to the skin of 23 humans for a 7-day period did not show any adverse effects (Shaffer et al., 1945*).

Two skin irritation studies in rabbits were performed according to OECD guideline 404 (BASF, 1986*; Hüls, 1987*) and another irritation study in rabbits was performed according to FDA recommended methods (Hüls, 1981*). In the first study, no erythema or oedema was observed (BASF, 1986*). In the second, very slight erythema was observed in all rabbits that persisted for 48 hours (Hüls, 1987*). In one rabbit, this progressed to a well-defined erythema. All reactions were reversible. The report concluded that DEHP was a slight skin irritant. The third earlier study reported that DEHP caused mild to moderate skin irritation at 24 hours after application in an unknown number of animals. Reactions were reversible (Hüls, 1981*).

Data not reported in previous evaluations

No data.

Conclusion

DEHP causes minimal skin irritation in rabbits. Limited data suggest no irritant effects in humans.

4.3.2 Eye irritation

Previous evaluations

Two eye irritation studies in rabbits were performed according to OECD guideline 404 (BASF, 1986*; Hüls, 1987*) and another eye irritation study in rabbits was performed according to FDA recommended methods (Hüls, 1981*).

No reaction was observed in the cornea or iris in any of the studies. All three studies reported mild conjunctival redness after one hour. In the earlier study, mild conjunctival redness was observed in five eyes, one hour after dosing and in three eyes, 24 hours after application (Hüls, 1981*). Where reported, all reactions resolved at later timepoints.

Data not reported in previous evaluations

No data.

Conclusion

DEHP causes minimal eye irritation in rabbits.

4.3.3 Respiratory irritation

Previous evaluations

No studies specifically addressing this issue have been found. One acute toxicity study included examination of the lungs. Exposure to 10 mg/L DEHP for 4 hours induced dark red foci and patches in the lungs of 19/31 rats (Hüls, 1981*; Klimisch et al., 1992*). It is unknown if these effects were reversible.

There are no adequate human data. In a case report of 3 preterm infants artificially ventilated with PVC respiratory tubes, an unusual lung disorder resembling hyaline membrane disease was observed in two infants, whilst the third died (Roth et al., 1988*). The authors assumed that these findings were causally related to the exposure to high doses of DEHP released from the PVC tubes.

Data not reported in previous evaluations

No data.

Conclusion

Data are insufficient to determine the respiratory irritant potential of DEHP.

4.4 Sensitisation

4.4.1 Skin sensitisation

Previous evaluations

In a human study (Shaffer et al., 1945*), 23 human subjects were subjected to patch tests (skin of the back) where DEHP was left in contact for 7 days and reapplied on the same spots 10 days later. There was no erythema or any other reaction at any time following application of undiluted DEHP.

Two skin sensitisation studies in guinea pigs, using the Magnusson-Kligman maximization test protocol (Hüls, 1981*) and the Buehler test protocol (Exxon, 1994*), reported no positive reactions.

Data not reported in previous evaluations

No data.

Conclusion

DEHP was not a skin sensitiser in a Magnusson-Kligman maximization test and a Buehler test in guinea pigs. Limited data indicate no sensitisation reactions in humans.

4.4.2 Respiratory sensitisation

Previous evaluations

A case control study was performed to assess the link between interior surface materials in the home and the development of bronchial obstruction (as an indicator for development of asthma) during the first two years of life (Jaakkola et al., 1999*). The results showed that the risk of bronchial obstruction was greater in the presence of PVC in the floor, but not wall, materials. The risk of bronchial obstruction increased in relation to the amount of plasticizer-emitting materials in the home.

In an earlier study by the same group (Oie et al., 1997), DEHP was predominant amongst different phthalates detected in sedimented dust samples (69% of total phthalate) and suspended particulate matter samples (52% of total phthalate) taken from dwellings.

An in vitro animal study provides limited support linking DEHP with respiratory hyperresponsiveness. MEHP (but not DEHP) provoked reversible hyperresponsiveness to methacholine in rat tracheal tissue (Doelman et al., 1990*). The authors concluded that only continuous exposure to DEHP might cause bronchial hyperresponsiveness.

Data not reported in previous evaluations

The EU Scientific Committee on Health and Environmental Risks (SCHER) published (29 May 2007) an opinion on the risk assessment on indoor air quality. With regard to phthalates, DEHP is considered to be the dominant phthalate in house dust and indoor air. In a study where the concentrations of DEHP were measured (Bornehag et al., 2004*), DEHP was found associated with asthma in children at the highest exposure quartile. Long-term exposure to DEHP (Larsen et al., 2007*) and its

metabolite, MEHP (Hansen et al., 2007*), together with a model allergen did not show promoting effects on the development of the allergen specific IgE antibodies. Based on the lack of mechanistic support and taking into account the low exposure level of phthalates by inhalation (Larsen et al., 2007*; Nielsen et al., 2007*), the SCHER did not find consistent scientific evidence which indicate that phthalates should be high concern chemicals in indoor air.

Conclusion

Human studies indicate correlations between the risk of bronchial obstruction and plasticiser-emitting components of the indoor environment. However, there is currently insufficient evidence supporting a causal relationship between respiratory effects and DEHP. Data are insufficient to determine the respiratory sensitization potential of DEHP.

4.5 Repeated dose toxicity

Previous evaluations

The toxicity of DEHP following repeated exposures has been evaluated exhaustively in many animal species, both over short-term and chronic periods (ECB, 2006). The studies are summarised in Appendix 2. Only key studies are detailed below.

Oral

DEHP has been tested via the oral route in many studies particularly in the rat but also in the mouse and marmoset monkey. Liver hypertrophy, increased liver weights and peroxisome proliferation were noted in most of the repeated dose studies. In a well performed 104-week dietary study in F-344 rats (70/sex/group) fed DEHP at 0, 100, 500, 2500 or 12500 ppm (0, 5.8-7.3, 28.9-36.1, 146.6-181.7 and 789-938.5 mg/kg bw/d males-females respectively), hepatotoxicity (significant increase in serum albumin, absolute and/or relative liver weights and peroxisome proliferation) was observed in both sexes at 2500 ppm (146.6-181.7 mg/kg bw/d) and above (Moore, 1996*).

As well as liver effects, testicular effects such as decreased weights, testicular atrophy, increased bilateral aspermatogenesis, immature or abnormal sperm forms, seminiferous tubular degeneration, Sertoli cell vacuolation or complete loss of spermatogenesis were evident in most of the repeated dose studies. A NOAEL of 50 ppm (3.7 mg/kg bw/d) for testicular effects was identified from a 13-week rat study conducted according to OECD guidelines and GLP (Poon et al., 1997). In this study, Sprague-Dawley rats (10/sex/dose) were fed DEHP at doses of 0, 5, 50, 500 or 5000 ppm (0, 0.4-0.4, 3.7-4.2, 37.6-42.2 or 375.2-419.3 mg/kg bw/d, males-females respectively). A LOAEL of 500 ppm (37.6 mg/kg bw/d) was established based on an increased incidence of Sertoli cell vacuolation. Significantly decreased absolute and relative testicular weights, mild to moderate seminiferous tubule atrophy and Sertoli cell vacuolation were observed at higher doses.

Increases in kidney weights, mineralisation of renal papilla, tubule cell pigments and chronic progressive nephropathy in the kidney were also observed in studies. The majority of these changes were seen in both sexes in different species in studies of varying durations. In chronic studies in rats and mice (Moore, 1996*; Moore, 1997*), there was no indication that these DEHP-related changes in the kidney were

reversible upon cessation of exposure. From the 104-week rat dietary study of Moore (1996*), a NOAEL for kidney effects was established at 500 ppm (28.9 mg/kg bw/d for males and 36.1 mg/kg bw/d in females). The LOAEL in this study was 146.6 mg/kg bw/d (males) and 181.7 mg/kg bw/d (females), based on increased absolute and relative kidney weights.

Dermal

In the only available dermal study, 0.2 mL of 10, 30, 50, or 100% DEHP in olive oil was administered percutaneously to mice for one month (Watari et al., 1978*). Macroscopically, the liver was greatly enlarged. Inflammatory signs were observed in the peritoneum in the two highest dose groups. Hepatic cells showed atrophied nuclei and frequently contained fat droplets. The authors concluded that DEHP is absorbed and accumulates in the liver. This study was considered to have several limitations (ECB, 2006).

Inhalation

Four inhalation studies in experimental animals are identified. In the first study, rats were exposed up to 1000 mg/m³, 6 hours per day, 5 days per week for 4 weeks (BASF, 1990*; Klimisch et al., 1992*). In the highest dose group, there was a significant increase in relative lung weights in male rats accompanied by foam cell (macrophage) proliferation and thickening of the alveolar septa. Liver weights were slightly increased but unusually, this was not accompanied by peroxisome proliferation that had been reported in a similar range-finding study conducted earlier by BASF (Merkle et al., 1988*). No testicular toxicity was detected histologically.

A poorly described study of male mice (20 animals) exposed to air saturated with vapours of DEHP (purity not specified) for 2 hours per day, 3 days per week, for 4-16 weeks failed to reveal consistent abnormalities which could be attributed to inhalation of DEHP (Lawrence et al., 1975*). No further data were available.

The only long-term inhalation study available was on hamsters (Schmezer et al., 1988*). However, only a single, very low dose (continuous inhalation of 15 µg/m³ for 23 months) was used. No signs of any toxicological effects were reported.

Parenteral

Several published reports were found on the effects of DEHP administered intravenously (IV) to animals (Jacobson et al., 1977*; Sjoberg et al., 1985b*; Greener et al., 1987*; Baxter Healthcare Corporation, 2000*; Cammack et al., 2003).

Jacobson et al. (1977*) studied hepatic effects in 6-month-old rhesus monkeys receiving transfusions of plasma from DEHP-plasticised PVC bags over a 6-month or 1 year period. The average total exposures to DEHP for the groups of monkeys transfused weekly for one year were: Group 1 (plasma stored at 20°C): 3 monkeys at a mean dose of 27 mg/kg bw; Group 2 (plasma stored at 4°C): 2 monkeys at a mean dose of 8 mg/kg bw; Group 3 (transfused biweekly for 6 months, platelet poor plasma stored at 22°C): 2 monkeys at a mean dose of 32 mg/kg bw; Group 4 (untransfused control group): 3 monkeys and Group 5 (platelet-rich plasma stored for 48 hours at 22 °C in polyethylene blood bags): 2 monkeys. Three of the seven monkeys transfused from DEHP-plasticised PVC bags showed some impairment of hepatic perfusion and four out of seven monkeys demonstrated abnormal sulfobromophthalein clearance indicative of subclinical liver disease. Six out of the seven had

abnormal liver histology (aggregates of inflammatory cells, hepatocyte degeneration, and multi- and bi-nucleated giant cells) upon completion of transfusion period that persisted in three of the five surviving monkeys throughout the follow-up period of 26 months. None of the five control animals had abnormal liver histology. The results of this study are confounded by the small sample size, inconsistent responses in the two groups that received the largest (and similar) doses, use of pooled plasma to re-transfuse into the monkeys and appearance of a tuberculosis outbreak in the monkey colony which might have contributed to the hepatic effects. The authors conceded that the observed hepatic effects were mild and could be attributed to background effects.

Sprague Dawley rats (5-6/group) were cannulated and 3 hour infusions of 0, 5, 50, or 500 mg/kg DEHP were performed daily every other day for a total of six infusions over 12 days (Sjoberg et al., 1985b*). This was equivalent to time-weighted average doses of 2.5, 25, and 250 mg/kg bw/d. The DEHP was emulsified with egg yolk phosphatides and administered in a glycerol solution. Animals were sacrificed 2-3 hours after the last infusion. The results showed a dose-related decrease in body weight gain, an increase in relative liver weight at the middle and highest doses but no change in clinical chemistry parameters. Liver and kidney histology appeared unchanged except for an increase in hepatic peroxisomes. There was no change in the relative weight of the reproductive organs but transmission electron microscopic examination revealed slight enlargements of the smooth endoplasmic reticulum in Sertoli cells at the highest dose in three of five rats. The NOAEL was 25 mg/kg bw/d, with hepatic changes at 250 mg/kg bw/d.

Rhodes et al. (1986*) reported an intraperitoneal marmoset study. Five marmosets were dosed with 1 g/kg bw/d in corn oil for 14 days. There was no indication of the length of time reported between the last dose and necropsy. At necropsy, blood was taken for toxicokinetic studies, a gross examination was made and selected tissues were subject to microscopic examination. The marmoset data were considered by CERHR (2005) to be confusing and poorly reported: a single set of bar graphs was presented, while two studies were performed. The authors stated that organ weights were not changed in marmosets at 1 g/kg bw/d but provided no data. Based on histology and biochemical measures, peroxisome proliferation was not induced in marmosets. The authors presented no histological findings of testes. This limits the study as testicular pathology is the most sensitive endpoint at this exposure duration, and poor histology could well mean that lesions could go undetected.

Cammack et al. (2003) conducted a 21-day repeat dose study of DEHP in neonatal (3- to 5-day old) rats. Rats were injected interperitoneally with 0, 60, 300 or 600 mg/kg bw/d. A second group of animals was dosed for 21 days then held for a recovery period until 90 days of age. Terminal body weight was significantly less in the high dose group only. At the end of the 21-day dosing period, mean liver weight was increased and mean testes weight was decreased in the two higher dose groups. Testicular atrophy was observed in all animals in the 300 and 600 mg/kg bw/d treatment groups. The NOAEL in the study was 60 mg/kg bw/d.

Human studies

Three preterm infants artificially ventilated through PVC respiratory tubes, developed unusual lung disorders resembling hyaline membrane disease during the fourth week of life. One infant died two weeks after birth; the other two were healthy at follow-up 20 months later. DEHP was detected in the lung after autopsy of the

infant who died. The estimated inhalation exposure in the three infants ranged between 1-4200 µg/h based on the concentrations of DEHP in the condensate collected from the water traps of the respirator tubing. However, this is likely to be an over-estimate as infants were not exposed to the condensate. DEHP, but not MEHP, could be demonstrated in urine samples (Roth et al., 1988*).

A morbidity study was carried out on a group of workers (97 men and 4 women) employed in a German plant producing DEHP (Thiess et al., 1978c*). The average exposure period was 12 years (range: 4 months to 35 years). DEHP levels measured in ambient air were generally low (0.001-0.004 ppm, ~ 0.016-0.064 mg/m³). Higher levels up to 0.01 ppm (~0.16 mg/m³) were measured near the chemical reactor. Blood lipids, serum activities of liver enzymes and routine haematological tests were normal, and no excess of any pathological condition was found. There was no referent group.

A mortality study of 221 workers exposed to DEHP in the same plant was also conducted (Thiess et al., 1978b*). Eight deaths occurred in the cohort compared with expected values of 15.9 and 17.0 for city and country workers, respectively. The cohort size was small and follow-up was short.

Three separate studies reported the incidence of polyneuropathy in workers exposed to phthalate esters (including DEHP). Milkov et al. (1973*) conducted a morbidity study in the USSR on 147 workers at a PVC-processing plant. The workers were exposed to a mixture of phthalates, including DEHP as a minor constituent. The total phthalate air concentrations recorded varied between 1.7 and 66 mg/m³. Polyneuropathy was evident in 47 workers (32%); the incidence increased with length of employment. Vestibular abnormalities were evident in 63 workers (78%) of 81 workers specifically examined. No referent group was included in the study.

In a cross-sectional study, symptoms and signs of polyneuropathy were reported in 12 out of 23 workers at a phthalate production plant in Italy (Gilioli et al., 1978*). The workers were exposed to a mixture of phthalates, including DEHP, but also to a lesser degree, to the corresponding alcohols and to phthalic anhydride. Total phthalate air concentrations varied between 1 and 60 mg/m³. No referent group was included in the study.

In a study involving a Swedish PVC-processing factory, 54 male workers were examined for anomalous peripheral nervous system symptoms and clinical signs (Nielsen et al., 1985*). The workers were exposed mainly to DEHP, diisodecyl phthalate, and butylbenzyl phthalate. They were divided into three groups of approximately equal size and mean phthalate exposures of 0.1, 0.2, or 0.7 mg/m³. Peripheral nervous system symptoms and signs displayed were not related to the level of exposure.

Data not reported in previous evaluations

McKee et al. (2004) describes a study reported as an abstract (Tomonari et al., 2003) of marmoset monkeys given DEHP orally (gavage) at doses of 0, 100, 500 or 2500 mg/kg bw/d for 65 weeks. At all doses tested, DEHP had no effects on liver and testicular weights. Weights of the other accessory male reproductive organs in the monkey were similarly unaffected by treatment. Microscopic examinations did not reveal any testicular lesions and there were no differences in sperm counts. No differences were observed in testicular 3-beta hydroxysteroid dehydrogenase levels

or peroxisome proliferator-activated receptor mRNA expression between control and DEHP-treated animals. The NOAEL from this study was 2500 mg/kg bw/d.

A subsequent report by Tomonari et al. (2006) describes 90-115 day old marmoset monkeys (5-6/sex/group) given DEHP at 0, 100, 500 or 2500 mg/kg bw by gavage for 65-weeks. Blood samples were taken throughout the study and analysed for DEHP, MEHP, zinc and testicular enzyme activity. At the end of the study, the liver and primary and secondary sex organs were weighed and examined histologically. Peroxisomal enzyme activities were measured in liver samples. There were no treatment-related changes in body weights, liver weights or male reproductive organ weights. Absolute and relative uterine weights were increased significantly at 500 mg/kg bw/d and absolute and relative ovarian weights were increased significantly at 500 and 2500 mg/kg bw/d. These increases were not dose related. There were no microscopic changes in male gonads, secondary organs, Leydig, Sertoli or spermatogenic cells. No increases in hepatic peroxisomal enzyme activities were noted. The NOAEL was 2500 mg/kg bw/d.

Kurahashi et al. (2005) exposed 4 week old male Wistar rats (4/group) to doses of DEHP at 0, 5 or 25 mg/m³, 6h per day, for 4 or 8 weeks. There were no differences in body or testes weights. Seminal vesicle weight was reduced after 8 weeks but not 4 weeks exposure to both doses. Histological examination showed no significant pathological changes in the testes after 4 or 8 weeks exposure to either dose. The study did not show a dose-response and included a small sample size.

Using PPAR α -null mice, Lapinskas et al. (2005) recently showed that expression of PPAR α is necessary for DEHP and dibutyl phthalate (DBP) induced liver effects (hepatomegaly and induction of fatty acid metabolising enzymes).

Conclusion

The toxicity of DEHP has been evaluated in a number of animal species, both short-term (few weeks) and life-time studies by several routes of exposure. The most pronounced findings included effects on the liver (hepatomegaly, peroxisome proliferation), testes (tubular atrophy) and kidneys (increased kidney weights, mineralisation of renal papilla, tubule cell pigments and chronic progressive nephropathy). Reproductive endpoints have been assessed particularly in later studies and will be described in greater detail in Section 4.8.

For hepatotoxicity, a well-conducted 104 week rat dietary study noted significant increases in serum albumin, absolute and/or relative liver weights and peroxisome proliferation in both sexes at 2500 ppm (146.6-181.7 mg/kg bw/d) and above (Moore, 1996*). The NOAEL for these effects was 28.9-36.1 mg/kg bw/d. Oral and inhalation studies in monkeys failed to elicit similar hepatotrophic effects at doses up to 2500 mg/kg bw/d, the maximum dose tested (Tomonari et al., 2003; 2006).

Kidney effects were also observed consistently following DEHP administration. From the 104-week rat dietary study of Moore (1996*), a LOAEL was established at 146.6-181.7 mg/kg bw/d, based on increased absolute and relative kidney weights. Mineralization of renal papilla, tubule cell pigmentation and chronic progressive nephropathy was observed at higher doses. The NOAEL for kidney effects was 500 ppm (28.9-36.1 mg/kg bw/d).

In addition to liver and kidney effects, testicular toxicity manifesting as decreased weights, testicular atrophy, increased bilateral aspermatogenesis, immature or

abnormal sperm forms, seminiferous tubular degeneration, Sertoli cell vacuolation or complete loss of spermatogenesis were evident in repeated dose studies. In a well-conducted 13-week rat dietary study, a LOAEL of 500 ppm (37.6 mg/kg bw/d) was established based on an increased incidence of Sertoli cell vacuolation (Poon et al., 1997). Significantly decreased absolute and relative testicular weights, mild to moderate seminiferous tubule atrophy and Sertoli cell vacuolation were observed at higher doses. The NOAEL was 50 ppm (3.7 mg/kg bw/d).

4.6 Genetic toxicity

Previous evaluations

The genotoxicity of DEHP has been reviewed extensively (IARC, 2000; ECB, 2006). DEHP has been tested in a variety of short-term genotoxicity assays with predominantly negative results. In 15 published Ames tests, all results were negative. The maximum concentration used was 14700 µg/plate. Two studies in fungi were negative, failing to show any evidence of mutation or recombination events. Primary DNA damage, mutation, sister chromatid exchange or chromosomal aberrations were not induced in cultured mammalian cells.

Results were generally negative in in vivo (mouse, rat and *Drosophila melanogaster*) studies testing DEHP and its main metabolites MEHP and 2-EH. Low levels of mutation but not DNA damage were induced in somatic cells of *Drosophila melanogaster*. Gene mutations were not induced in vivo in the liver of dosed mice and there was no evidence of chromosomal aberrations in mice or rats in vivo.

Human studies

The frequency of chromosomal aberrations in blood lymphocytes were investigated in ten workers employed from 10-30 years in a DEHP production plant in Germany (Thiess & Fleig, 1978*). Exposure levels ranged from 0.0006 to 0.01 ppm (0.01-0.16 mg/m³). There was no evidence of increased frequencies of chromosome aberrations in the exposed workers. The small number of workers examined and low levels of exposure limits this study.

Data not reported in previous evaluations

No data.

Conclusion

Based on weight-of-evidence, DEHP is considered to be non-genotoxic.

4.7 Carcinogenicity

Previous evaluations

Numerous studies on the carcinogenicity and mechanisms of carcinogenicity of DEHP have been performed in vivo and in vitro. Several in vitro mammalian cell transformation assays have been performed on DEHP and metabolites. Some, but not all, report positive transforming potential in the presence or absence of metabolic activation.

ECB (2006) summarises several in vivo tumour initiation/promotion experiments in rats and mice where the measured effect was the number and/or volume of altered liver cell foci. Overall, data indicate that DEHP has no tumour initiating activity, a positive promoting activity in mouse liver and a weak or no promoting activity in rat liver.

In a carcinogenicity study, B6C3F1 mice (70/sex/group) received DEHP in the diet at concentrations of 0, 100, 500, 1500, or 6000 ppm (m/f: 0/0, 19.2/23.8, 98.5/116.8, 292.2/354.2, or 1266.1/1458.2 mg/kg bw/d) for 104 weeks (Moore, 1997*). In an additional recovery group, mice were dosed with 6000 ppm of DEHP for 78 weeks, followed by a 26-week recovery period. Significantly increased incidences of hepatocellular adenomas and carcinomas were observed at 1500 ppm and 6000 ppm in male mice. In these two high dose groups, induction of peroxisome proliferation but not hepatocellular proliferation was more pronounced in both sexes. In the 6000 ppm recovery group, the incidence of hepatocellular adenomas, but not carcinomas, was less than in the 6000 ppm group. Non-tumour endpoints are described in Section 3.5.1. The LOAEL for tumour induction (hepatocellular neoplasms in male mice) in this study was 1500 ppm (292 mg/kg bw/d). The NOAEL was 500 ppm (98 mg/kg bw/d).

In a chronic/carcinogenicity study, F344 rats (70/sex/group) received DEHP in the diet at doses of 0, 100, 500, 2500, or 12500 ppm (m/f: 0/0, 5.8/7.3, 28.9/36.1, 146.6/181.7, or 789/938.5 mg/kg bw/d) for 104 weeks (Moore, 1996*). In an additional recovery group, rats (55/sex/group) were administered 12500 ppm DEHP for 78 weeks, followed by a 26-week recovery period. Increases in hepatocellular adenomas and mononuclear cell leukaemia (MCL) in males at 2500 ppm and above and hepatocellular carcinomas in males and females at 12500 ppm, were observed. However, the incidence of hepatocellular adenomas/ carcinomas was decreased in recovery animals at 12500 ppm (2-week recovery period), compared with the same dose group at the end of the dosing period. Peroxisome proliferation was induced from 2500 ppm. Effects on the liver, kidney and testis induced at 2500 ppm and above are described in Section 3.5.1. The LOAEL for tumour induction (hepatocellular neoplasms and MCL in male rats) was 2500 ppm (147 mg/kg bw/d for males). The NOAEL was 500 ppm (28.9 mg/kg bw/d, males).

The carcinogenicity of DEHP was tested in rats and mice in the US National Toxicology Program (NTP) in 1982-1983 (Kluwe et al., 1982*; NTP, 1982*; Kluwe et al., 1983*). F-344 rats and B6C3F1 mice were fed diets containing 0, 6000 or 12000 ppm (rats), and 0, 3000 or 6000 ppm (mice) DEHP for 103 weeks. This corresponded to a daily DEHP intake of 0, 322, and 674 mg/kg bw/d for male rats; 0, 394, and 774 mg/kg bw/d for female rats; 0, 672 and 1325 mg/kg bw/d for male mice, and 0, 799 and 1821 mg/kg bw/d for female mice. There was a dose-dependent increased incidence of hepatocellular carcinomas in male and females rats, with the increase statistically significant in females at the highest dose. The combined incidence of rats with hepatocellular carcinomas or neoplastic nodules was significantly greater than controls for females at both doses and for high dose males. In mice, a dose-related trend for hepatocellular carcinomas was observed for both sexes, with a significant increase in females at both doses and in high dose males. The incidence of hepatocellular carcinomas or adenomas when combined was dose-related, with a significant increase in both sexes at both doses. The LOAEL for tumour induction in rats and mice was 6000 ppm (320 mg/kg bw/d for male rats) and

3000 ppm (670 mg/kg bw/d for male mice) respectively. No NOAEL could be identified for either species.

DEHP was administered in the diet at 0, 30, 95, and 300 mg/kg bw/d to male Sprague-Dawley rats beginning at an age of 90 - 110 days and continuing for the remaining lifetime of the animals (up to 159 weeks) (Voss et al., 2005). Significantly increased incidences of hepatocellular adenomas and carcinomas were observed at the highest dose. The percentage of benign Leydig cell tumors in the highest dose group was almost twice as high as the percentage in the control group (28.3% versus 16.4%). There was a significant dose-related trend in incidence of hepatic neoplasms and Leydig cell tumours. The time-to-tumour analysis showed that the significantly higher incidence of Leydig cell tumours in this rat strain occurred even earlier than hepatocellular tumours. In addition, multiplicity of the DEHP-induced Leydig cell tumours increased with time in contrast to spontaneous Leydig cell tumours, which were mostly unilateral. In this study, the NOAEL for both liver and testicular carcinogenic effects was determined to be 95 mg/kg bw/d for the Sprague-Dawley strain. However, a trend of increased Leydig cell tumours was observed starting at lower doses, 30 and 95 mg/kg bw/d (Voss et al., 2005).

The only inhalation study available is on Syrian golden hamsters continuously exposed to 15 µg/m³ of DEHP by inhalation for 23 months (Schmezer et al., 1988*). There was no significant increase in tumour incidence.

Human studies

In a prospective cohort mortality study, eight deaths (including one carcinoma of the pancreas and one bladder papilloma) were observed (expected values of 15.9 and 17.0 from the city and county data, respectively) among 221 workers exposed to DEHP for periods of 3 months to 24 years (average 11.5 years) (Thiess et al., 1978b*). No information about exposure levels is given in the report, however in two other reports by the same group, exposure levels in the plant ranged from 0.0006 to 0.01 ppm (0.01-0.16 mg/m³) are given (Thiess & Fleig, 1978*; Thiess et al., 1978a*).

Occupational exposure to polyvinyl chloride (PVC) and other products in the plastics industry were assessed in a case-control study on testicular cancer using self-administered questionnaires (148 cases and 315 controls) (Hardell et al., 1997*). An increased risk was observed for exposure to PVC (an increased odds ratio of 6.6; 95% confidence interval, 1.4-32), but not for other types of plastics.

Data not reported in previous evaluations

Hardell's earlier study was followed up by a larger case-control study taken from the Swedish Cancer Registry during 1993-1997 (Hardell et al., 2004). A total of 791 matched pairs completed a questionnaire regarding exposure. Overall exposure to PVC plastics gave an odds ratio (OR) of 1.35 (confidence interval = 1.06-1.71). No dose-response relationships were found. The results do not support their previous study. There was no clear association with testicular cancer and exposure to PVC.

Conclusion

The results show that DEHP is carcinogenic in rats and mice. A statistically significant increase in the incidence of hepatocellular tumours with a dose-response relationship was observed in rats and mice of both sexes and a significant dose-related increase in the incidence of Leydig cell tumours was observed in male rats. It

was also noted that low doses did not cause hepatocellular tumours, which suggests a threshold for this effect.

Leydig cell tumours have been reported in only one study in Sprague–Dawley rats at doses that have been used in two other studies using F344 rats. In a 104-week F344 rat study, an increased incidence of mononuclear cell leukaemia (MCL) was also noted. The relevance of MCL is unknown, but it was only seen in one of two rat studies and in neither of the two mouse studies. Moreover, this tumour type is well known to occur spontaneously with high incidence in the F344 rat strain used in the study.

The LOAEL and the NOAEL for tumour induction in rats (both liver tumours and MCL) were established as 2500 ppm (146.6 mg/kg bw/d for males) and 500 ppm (28.9 mg/kg bw/d for males), respectively (Moore, 1996*). In mice, the LOAEL and the NOAEL for induction of liver tumours were 1500 ppm (292 mg/kg bw/d for males) and 500 ppm (98 mg/kg bw/d for males), respectively (Moore, 1997*).

A single human case-control study suggested an increased risk of testicular cancer from DEHP in the PVC industry. However, a larger follow-up study did not support these findings. Overall, data are inadequate to determine the carcinogenicity of DEHP in humans.

4.8 Reproductive toxicity

Traditional hazard assessments consider effects on fertility separate from developmental toxicity. Fertility is tested by exposing sexually mature adults to a chemical and examining the effects on reproductive capacity. Developmental toxicity is studied by exposing pregnant dams and looking for effects on the foetuses. Chemicals that affect the developing reproductive system following prenatal exposure may also affect sexual maturation or functional reproductive disorders that are only apparent at maturity. Developmental toxicity can therefore lead to effects on fertility and the two endpoints cannot be clearly distinguished.

In this hazard assessment, data are presented on the basis of test procedure. The effects on fertility (as adults) and development (as foetuses) are then discussed separately. Reproductive and developmental data are summarised in Appendix 3.

4.8.1 Human studies

Previous evaluations

The following information was summarised from FDA (2002), ATSDR (2002), CERHR (2005) and ECB (2006). The studies are summarized in Appendix 3.

There are limited data available on the reproductive toxicity of DEHP or its major metabolites in humans. Several studies associating adult male MEHP levels and various reproductive endpoints are described below.

Modigh et al. (2002*) evaluated time-to-pregnancy in the partners of men potentially exposed occupationally to DEHP by inhalation. Median time-to-pregnancy was 3.0 months in the unexposed group, 2.25 months in the low exposure group ($< 0.1 \text{ mg/m}^3$), and 2.0 months in the high-exposure group ($0.1\text{-}0.2 \text{ mg/m}^3$). The authors concluded that there was no evidence of a DEHP-associated prolongation in time-to-

pregnancy, although they recognized that there were few highly exposed men in their sample.

In a series of related human studies, spot urinary MEHP and semen and sperm motion parameters and sperm DNA damage were evaluated (Duty et al., 2003a; Duty et al., 2003b; Duty et al., 2004; Duty et al., 2005). The relationship between serum concentrations of reproductive hormones and MEHP urine concentrations was also assessed. Subjects included more than 150 men attending a clinic as part of a fertility evaluation. There were no significant associations between abnormal semen parameters, serum testosterone, sperm DNA damage and MEHP urine concentration above or below the group median. Jonsson et al. (2005) also studied semen parameters and urinary phthalate monoester levels in 234 military recruits. There were no significant associations between highest versus lowest urinary MEHP quartile and any of the dependent variables.

Cobellis et al. (2003*) measured DEHP and MEHP concentrations in the plasma and peritoneal fluid of 35 women identified by laparoscopy as having endometriosis. There was no difference in the proportion of surgical patients compared to control women with detectable DEHP or MEHP (91.4% compared to 92.6% respectively). There was a significant difference in the median concentration of DEHP in the patients compared to control women (0.57 µg/mL compared to a control value of 0.18 µg/mL) but no difference in median MEHP concentration.

The human studies are limited but are consistent in that they do not identify any significant associations between MEHP and adverse semen parameters, hormone levels, time-to-pregnancy, or infertility diagnosis.

There have been several studies in humans where development of the male reproductive system and estimates of DEHP exposure during pregnancy or early childhood have been evaluated.

Cord blood samples were collected from 84 consecutive newborns (including a set of twins) delivered at an Italian hospital (Latini et al., 2003). DEHP and/or MEHP were detected in 74 of 84 cord blood samples with a mean (range) DEHP cord blood serum concentrations of 1.19 (0–4.71) µg/mL and MEHP of 0.52 (0–2.94 µg/mL). Mean gestational age, but no other parameter, was significantly lower in MEHP-positive neonates (38.16 weeks) versus MEHP-negative neonates (39.35 weeks). However, the levels measured in blood were unusually high compared to other studies.

Main et al. (2006) reported phthalate concentrations in pooled milk samples collected 1–3 months after birth from 65 Finnish and 65 Danish women as part of a study of cryptorchidism and hormone levels in male children. Phthalate monoesters mono-methyl phthalate (mMP), monoethyl phthalate (MEP), mono-*n*-butyl phthalate (MBP), monobenzyl phthalate (MBzP), MEHP and mono-isononyl phthalate (MiNP) were measured in milk and gonadotropins, sex-hormone binding globulin (SHBG), testosterone, and inhibin B were measured in the serum of breast fed boys. Cryptorchidism was identified in 62 of the 130 children of these women. However, there was no significant association between milk phthalate concentrations and cryptorchidism.

Association between 11 maternal urinary phthalate monoester concentrations and genital parameters such as anogenital index (AGI) [i.e. anogenital distance (AGD) normalized for body weight] and testicular descent in children was investigated in 85 mother-son pairs (Swan et al., 2005). There was no significant association between

maternal urinary MEHP concentration and infant AGI. However, urinary concentrations of four other phthalate metabolites MEP, MBP, MBzP and monoisobutyl phthalate (MiBP) were inversely related to AGI. This study has been criticised by McEwen et al. (2006) from the Cosmetic and Fragrance Associations of America and Europe. They suggested that AGD is more likely to be proportional to height rather than weight and that maternal phthalate urinary concentrations were not normalized for urine volume. The reliability of the measurement of AGD in humans has not been verified. One study of 87 neonates that has assessed the correlation of AGD with body weight found in males a correlation of 0.48 and that body length may be a slightly better predictor for AGD than weight (Salazar-Martinez et al., 2004).

Rais-Bahrami et al. (2004*) examined onset of puberty and sexual maturity parameters in 14 to 16-year-old adolescents (13 males and 6 females) who had been subjected to extracorporeal membrane oxygenation (ECMO) as neonates. Pubertal development was normal. Thyroid, liver and kidney function, LH, FSH, testosterone and 17 β -oestradiol levels were normal for this stage of pubertal development.

Colon et al. (2000) compared blood phthalate levels in 41 premature thelarche patients and 35 controls. There was a statistically significant difference in average blood DEHP levels. DEHP was detected in 25 of the samples from premature thelarche patients at a mean concentration of 450 μ g/L (187 - 2098 μ g/L); MEHP concentration ranged from 6.3 to 38 μ g/L. DEHP was detected in 5 of 35 blood samples from control patients at a mean concentration of 70 μ g/L (276–719 μ g/L). The reported levels in the control group are unusually high compared with the background MEHP concentration in urine in the normal population (mean 4.27, range 3.80–4.79 μ g/L; Silva et al., 2004) and may reflect patient exposure to medical procedures within the hospital.

Data not reported in previous evaluations

Pan et al. (2006) measured the gonadotropins and gonadal hormone levels of 74 male workers exposed to elevated levels of DBP and DEHP in a PVC factory. Urinary MBP and MEHP levels (normalized to creatine) were significantly higher in exposed workers compared with controls (MBP 644.3 μ g/g versus 129.6 μ g/g; MEHP 565.7 μ g/g versus 5.7 μ g/g). Free testosterone was significantly lower in exposed workers (8.4 μ g/g) versus control workers (9.7 μ g/g) and was negatively correlated with MBP and MEHP.

4.8.2 Repeat dose toxicity studies

The effects of DEHP on reproductive endpoints have been tested in a variety of species including rats, mice, hamsters, ferrets and marmoset monkeys. The rat was the most sensitive followed by mice, hamsters and ferrets. Marmosets appear to be insensitive to DEHP-induced testicular toxicity. Key studies are described below.

Previous evaluations

Oral

Poon et al. (1997) exposed groups of 4-6 week old male and female Sprague-Dawley rats to 0, 5, 50, 500 and 5000 ppm DEHP in the diet for 13 weeks. Animals were reported to reach sexual maturity approximately 50 days into the study and thus were

immature for only part of the study. These dietary concentrations corresponded to average DEHP doses of 0, 0.4, 3.7, 38, and 375 mg/kg bw/d, for the male rats. In the testes, Sertoli cell vacuolation, described as “mild,” was seen in 7/10 males in the 500 ppm group, and 9/10 males in the 5000 ppm group. The highest group also showed bilateral, multifocal, or complete atrophy of the seminiferous tubules with complete loss of spermatogenesis and cytoplasmic vacuolation of the Sertoli cells lining the tubules. There was no measurement of reproductive function. The LOAEL, based on the testicular effects (Sertoli cell vacuolation) was 38 mg/kg bw/d and the NOAEL was 3.7 mg/kg bw/d.

David et al. (2000a) fed 6-week old Fischer 344 rats (50-80 males/group) diets containing 0, 100, 500, 2500, or 12500 ppm DEHP (0, 5.8, 29, 147, and 789 mg/kg bw/d for males) for 104 weeks. Testes weight (absolute and relative) was reduced in rats of the high-dose group. Aspermatogenesis was observed in all rats in the highest dose group at study week 78 but not in rats treated with 2500 ppm or in the control group. At study week 105, the incidence of aspermatogenesis was significantly increased in rats exposed to 100 ppm and higher. The percentage of rats with aspermatogenesis from the control to high-dose group was 58, 64, 78, 74, and 97%, respectively. The authors identified the LOAEL for aspermatogenesis as 147 mg/kg bw/d and the NOAEL as 29 mg/kg bw. However, CERHR (2005) concluded that the findings indicate a NOAEL for testis effects of 5.8 mg/kg bw/d, because of the clear dose-response increase in the proportion of each group showing aspermatogenesis. However, this NOAEL may not be reliable because of the high frequency of aspermia in the controls. In fact the authors suggest that an increased incidence of aspermia may be a normal occurrence in the aging rat. CERHR (2005) also suggested that suboptimal testis fixation may have obscured any early vacuolar lesions produced by DEHP.

Akingbemi et al. (2001, 2004) exposed rats to DEHP in two experimental series. In the first study to determine effects of gestational or lactational exposure, DEHP was administered daily by gavage in corn oil at 0 or 100 mg/kg bw/d to pregnant or nursing dams. In addition, to determine effects from exposure at different developmental ages, prepubertal male rats were dosed with 0, 1, 10, 100, or 200 mg/kg bw/d in two different 14 day periods: postnatal days (PND) 21–34 or 35–48 or for a longer 28 day period of PND 21–48.

In the second study (Akingbemi et al., 2004), young rats were gavaged daily with 0, 10 or 100 mg/kg bw/d DEHP on PND 21–48, 21–90 or 21–120. Within 24 hours of the final dose, measurements of LH and testosterone were made and the animals killed. Testicular histology was evaluated. Leydig cells were obtained from rats and incubated with LH to stimulate testosterone synthesis. Leydig cells were also incubated with testosterone biosynthesis substrates and enzyme activity measured.

There were no treatment-related effects on body weight gain or food consumption. There was no effect of DEHP treatment in young adults at any tested dose, on serum testosterone or LH or on in vitro Leydig cell steroidogenesis. There were no effects of any treatment on testicular histology. Treatment of prepubertal rats for 14 days (PND 21–34 or PND 35–48) did not produce alterations of serum LH or testosterone, but longer treatment (on PND 21–48) produced increases in serum LH and testosterone and interstitial fluid testosterone that were statistically significant at 10 mg/kg bw/d. This study suggests that younger rats are more sensitive to the effects of DEHP and that there was a threshold duration of exposure.

Leydig cells isolated from prepubertal rats that had been treated on PND 21–34 or 35–48 showed a decrease in basal and LH-stimulated testosterone production at and above 100 and 10 mg/kg bw/d, respectively. There were no treatment effects on cultured Leydig cells derived from 35- and 90-day-old rats that had been prenatally exposed to 100 mg/kg bw/d DEHP. Paradoxically, exposure of prepubertal rats for 28 days (PND 21–48) was associated with an increased Leydig cell synthesis of testosterone and LH. Exposure on PND 35–48 affected all tested enzyme activities, with the most sensitive being 17 β -hydroxysteroid dehydrogenase (reduced 74% at 10 mg/kg bw/d compared to control; other enzyme activities were significantly reduced at DEHP dose levels of 100 or 200 mg/kg bw/d). There were no effects of any treatment on testicular histology in any of the groups exposed during pregnancy, lactation, and post-weaning stages. The LOAEL was 10 mg/kg bw/d for increased serum LH and testosterone in rats exposed from PND 21–48 and the NOAEL was 1 mg/kg bw/d.

Dostal et al. (1988) gave Sprague-Dawley rats oral doses of 0, 10, 100, 1000, or 2000 mg/kg bw/d of DEHP (>99% pure) by gavage in corn oil for 5 days (7–10 animals per group) at 1, 2, 3, 6, and 12 weeks of age. Absolute and relative testis weights were significantly reduced at doses of 1000 mg/kg bw/d in 1, 2, 3, and 6-week-old but not in 12-week-old rats compared to controls of the same age suggesting differential age sensitivity. Doses of 2000 mg/kg bw/d were fatal to suckling rats and caused decreased relative testis weight but no lethality in 6- and 12-week-old rats. The number of Sertoli cell nuclei per tubule was reduced by 35% at 1000 mg/kg bw in neonatal rats; two- and three-week old rats showed loss of spermatocytes but not of Sertoli cells. Loss of spermatids and spermatocytes in 6- and 12-week old rats at 1000 and 2000 mg/kg bw/d was shown. These results suggest that Sertoli cells are more sensitive during their proliferative stage.

Sjoberg et al. (1986) studied the age-dependent testis toxicity of DEHP (1000 and 1700 mg/kg bw/d in the diet for 14 days) in rats at 25, 40, and 60 days of age. Body weight gain was retarded in all dosed groups and testicular weight was markedly reduced in 25- and 40-day-old rats given 1700 mg/kg bw/d. Severe testicular damage was shown for the 25-day- and 40-day-old rats at both dose levels. No changes were found in the 60-day-old rats.

A single bolus dose of DEHP (20, 100, 200, and 500 mg/kg bw) was given in corn oil to five neonatal rats (three-day old, CD Sprague-Dawley) pups per group (Li et al., 2000). MEHP (393 mg/kg bw), 2-EH (167 mg/kg), or vehicle was administered by gavage to 4 pups per group. All pups were killed 24 hours after dosing. The doses of MEHP and 2-EH were molar equivalent with 500 mg/kg DEHP. A time-course study was also conducted following a single dose of DEHP (200 mg/kg bw), where the pups were killed after 6, 9, 12, 24, or 48 h. Morphological examination revealed a dose-dependent presence of abnormally large, multi-nucleated germ cells (gonocytes) by 24 h post-treatment with DEHP (100–500 mg/kg bw). Sertoli cell proliferation was dose-dependently decreased from 100–500 mg/kg bw DEHP but not 20 mg/kg bw DEHP. There was a rebound in Sertoli cell proliferation at 48 hours following treatment with 200 mg/kg bw DEHP. MEHP (single dose group) induced similar effects as DEHP. A NOAEL for young pups of 20 mg/kg bw is derived for effects on altered gonocyte morphology and decreased Sertoli cell proliferation by a single oral dose of DEHP.

Two studies have administered oral doses of DEHP to pre- and post-pubertal marmosets for varying durations (Kurata et al., 1998*; Mitsubishi Chemical Safety Institute, 2003). Reproductive outcomes in particular were assessed.

Kurata et al. (1998*) administered groups of 4 male and 4 female 12–15 months old (post-pubertal) marmosets, doses of 0, 100, 500, or 2500 mg/kg bw/d DEHP in corn oil by gavage for 13 weeks. There were no treatment-related decreases in testis weight, testosterone and oestradiol levels. There were no testicular histopathological changes even at the highest dose. The NOAEL was 2500 mg/kg bw/d.

The authors of the Mitsubishi-Chemical-Safety-Institute (2003), in an unpublished report, administered DEHP by gavage in corn oil to juvenile marmosets (9 males and 6 females) beginning at 90–115 days of age until 18 months of age (young adulthood) at dose levels of 0, 100, 500, and 2500 mg/kg bw/d. Both males and females were assessed with in-life hormonal assays and with histopathology at necropsy. The results suggest little effect on testicular structure or function. Mean serum testosterone levels were highly variable, but the data suggested the possibility of a delay in the onset of puberty in male marmosets with increasing DEHP dose. Body weights and male organ weights were not affected. The NOAEL was 2500 mg/kg bw/d.

Inhalation

In a 4-week inhalation study conducted according to OECD guideline 412, male Wistar rats (10 rats per group) were exposed 5 days per week, 6 hours per day to 0, 0.01, 0.05, or 1 mg DEHP/L (0, 10, 50, or 1000 mg DEHP/m³) (99.7% pure) as liquid aerosol (Klimisch et al., 1992*). The males were mated to untreated females. No effects on male fertility were observed 2 and 6 weeks after the end of exposure and no testicular toxicity was detected histologically. However, the results were not presented, and peroxisome proliferation also was not observed.

Parenteral

Sjoberg et al. (1985b) exposed 25 or 40 day old rats to 0, 5, 50 or 500 mg/kg bw intravenously every other day for 10 days (time-weighted average 0, 2.5, 25 or 250 mg/kg bw/d). There was no change in testes weight but vacuolization of the Sertoli cells and spermatocyte degeneration was observed at 250 mg/kg bw/d. The NOAEL was 25 mg/kg bw/d.

In the second study, neonatal male rats or rabbits were injected with either 62 mg/kg bw/d DEHP or 4% bovine serum albumin during PND 3-21 (rats) or 14-42 (rabbits) (Baxter Healthcare Corporation, 2000*). Histopathological examination of the testes and other organs of DEHP-exposed animals revealed no alterations at this dose.

Similarly, Cammack et al. (2003) conducted a 21-day repeat dose study of DEHP in neonatal (3- to 5-day old) rats. Rats were injected with 0, 60, 300 or 600 mg/kg bw/d or gavaged with 300 or 600 mg/kg bw/d. A second group of animals was dosed for 21 days then held for a recovery period until 90 days of age. At the end of the 21-day dosing period, testicular atrophy, decreased seminiferous tubules diameter and mild depletion of germinal epithelial cells were observed at 300 mg/kg bw/d. Although testicular atrophy persisted at the end of the recovery period, histopathological changes were not seen in the recovery group previously exposed to a DEHP dose of 300 mg/kg bw/d for 21 days. At equivalent doses, oral exposure induced more

significant changes in testicular weight and pathology. The NOAEL for intravenous exposure in the study was 60 mg/kg bw/d and the LOAEL was 300 mg/kg bw/d.

Data not reported in previous evaluations

Tomonari et al. (2006) gave 90-115 day old marmosets (5-6/sex/group) 0, 100, 500 or 2500 mg/kg bw/d by gavage for 65 weeks. Blood samples were taken throughout the study and analysed for DEHP, MEHP, zinc and testicular enzyme activity. At the end of the study, the liver, primary and secondary sex organs were weighed and examined histologically. There were no treatment-related changes in male organ weights, no microscopic changes in male gonads, secondary organs, Leydig, Sertoli or spermatogenic cells. No increases in hepatic peroxisomal enzyme activities were noted. The NOAEL was 2500 mg/kg bw/d.

4.8.3 Continuous breeding reproductive toxicity studies

Previous evaluations

Lamb et al. (1987) gave DEHP to male and female CD-1 mice (20 pairs per breeding group) at dietary levels of 0, 0.01, 0.1, or 0.3% (0, 14, 140, and 425 mg/kg bw/d) from a 7-day premating period to 21 days after delivering litters (14 weeks in total). Decreased litters and viable pups were observed at 0.1% and above. No pairs were fertile at 0.3%. Also at 0.3% (the only dose examined), increased liver weights and decreased weights of the reproductive organs in parental animals (testes, epididymes, prostate, and seminal vesicles) were evident. All but one of the high-dose males showed some degree of bilateral atrophy of the seminiferous tubules. This dose also caused decreased sperm motility and sperm concentrations and increased incidences of abnormal sperm. The LOAEL was 0.1 % (140 mg/kg bw/d) based on decreased fertility and the NOAEL was 0.01% (14 mg/kg bw/d).

4.8.4 Two- and three-generation reproductive toxicity studies

Previous evaluations

Schilling et al. (2001) fed Wistar rats (25 males and females in each group) DEHP in the diet at doses of 0, 1000, 3000, or 9000 ppm (0, 113, 340, or 1088 mg/kg bw/d) for two successive generations, from at least 70 days premating of the first parental generation. Increased focal tubular atrophy in the testis was observed in all treated groups (F0, F1 and F2). Decreased food consumption, body weight gain, testis weights and fertility index were seen in F0 and F1 adults at 9000 ppm. Decreased body weight gains, total number of pups, delayed vaginal opening and preputial separation, and increased numbers of stillborn pups were observed in F1 and/or F2 at 9000 ppm. Decreased AGD was observed from 1000 ppm and was statistically significantly different from 3000 ppm. Severe effects on testicular histology, sperm morphology, fertility, and sexual development of the offspring occurred in both generations at 9000 ppm. Reduced testis weights in F2 and focal tubular atrophy were observed in male offspring in F1 and F2 at 3000 ppm. Focal tubular atrophy also occurred at 1000 ppm. Vacuolisation of Sertoli cells was only observed in atrophic tubuli, which were present in all exposed groups. There was no indication that Sertoli cell vacuolation preceded focal or diffuse tubular atrophy and subsequent loss of sperm production. A NOAEL for fertility was not established as Sertoli cell vacuolation was recorded in the F1 offspring generation from the lowest dose level, 1000 ppm (113 mg/kg bw/d). A developmental NOAEL was not established as

Sertoli cell vacuolation was recorded in the F1 offspring generation at the lowest dose level, 1000 ppm (113 mg/kg bw/d).

Wolfe & Layton (2003) fed Sprague-Dawley rats (17 males and females in each group) DEHP in the diet at concentrations of 1.5, 10, 30, 100, 300, 1000, 7500, and 10000 ppm (0.1, 0.5-0.8, 1.4-2.4, 4.8-7.9, 14-23, 46-77, 359-592, and 543-775 mg/kg bw/d) for two successive generations. The F0 generation began exposure as adults. Clinical signs were generally comparable among all groups in all generations and were not treatment-related in incidence or severity. In the F0 adults, a decreased number of live pups per litter were noted at 7500 ppm (592 mg/kg bw/d) and above. The only reproductive effects in the F0 rats occurred at 10000 ppm and included decreases in sperm counts and velocity, reductions in testis and epididymis weights, and increased numbers of rats with small testes in association with minimal-to-marked atrophy of seminiferous tubules characterized by loss of germ cells. The lowest dose level producing effects in F1 offspring was 7500 ppm (391 mg/kg bw/d) and included decreases in number of live pups/litter, reduced male AGD, delayed testes descent, vaginal opening and preputial separation.

Fertility was compromised in the F1 rats in the 10000 ppm group which did not produce any viable litters. Other reproductive effects observed in F1 parents were similar to those observed in F0 parents but usually occurred at lower dose levels. For example, minimal to marked seminiferous tubule atrophy was noted at 10000 ppm in the F0 and F1 males, and at 7500 ppm in the F1 and F2 males. Minimal atrophy was noted in 1 of 10 F1 males at 100 and 300 ppm. In the non-mating F1 adult males of the 300 ppm group there was a small increase in the number of animals (3 of 45) with small testes and/or epididymides (none were observed in the F0 males). The effects were not observed at the next higher dose (1000 ppm), but small testes were observed in 10 of 30 males of the 7500 ppm non-mating group. In F2 non-mating males, small testes were also observed in 1 of 21 animals at 300 ppm and 1-3 animals at 1000 ppm. Small testes and epididymides were also observed in 7500 ppm F3 males. While Sertoli cell vacuolation was observed in seminiferous tubules of the 1000 and 7500 ppm F1 males (not 10000 ppm males), the vacuolation was similar to that in the controls. It was concluded that the vacuolation observed resulted from distortion during fixation and processing of the tissues (ECB, 2006). This distortion could also have obscured any minimal toxic effects that may have been present.

Increased liver weights were observed at 1000 ppm and above with accompanying histopathological changes. Decreased terminal body weights were observed at 7500 ppm and above. There was no general toxicity observed at doses below 1000 ppm. For fertility effects, the NOAEL was 1000 ppm (46 mg/kg bw/d) and the LOAEL was 7500 ppm (592 mg/kg bw/d) based on impaired litter parameters (F1 pups). For developmental effects, the NOAEL was 100 ppm (4.8 mg/kg bw/d) and the LOAEL was 300 ppm (14 mg/kg bw/d) based on small testes size and minimal seminiferous tubule atrophy in the F1 and F2 generation. The case of a single male showing atrophy of seminiferous tubules in testis at 100 ppm was not considered significant, as there were no other accompanying findings.

4.8.5 Developmental/postnatal toxicity studies

Previous evaluations

The effect of DEHP on Leydig cell function in male Long-Evans rats exposed in utero (GD 12-21), during nursing, or during post-weaning stages has been evaluated

(Akingbemi et al., 2001). DEHP was administered to dams by gavage in corn oil at 0 or 100 mg/kg bw/d. Males were obtained for evaluation on PND 21, 35, or 90 (7 dams/group/stage). There were no effects of treatment during gestation on dam weight or weight gain or on offspring weight. Offspring testis and seminal vesicle weights also were not affected by treatment during gestation. Serum testosterone was reduced 31%–33% and serum LH was reduced 50%–64% in 21- and 35-day-old males exposed to DEHP during gestation. There were no effects on serum testosterone or LH in 90-day-old males. Prenatal exposure to DEHP resulted in decreased testosterone production by cultured progenitor Leydig cells obtained from 21-day-old males. Basal testosterone production was reduced 47%, and LH-stimulated testosterone production was reduced 56%.

The effects of DEHP were studied on male reproductive parameters in Sprague-Dawley rats exposed to 750 mg/kg/d DEHP by gavage commencing on GD 14 and ending at postnatal day (PND) 3 (Parks et al., 2000*). Exposed dams were sacrificed at GD 17, 18, 20, and at PND 2. Ex vivo testicular production of testosterone, testicular content of testosterone, and whole-body testosterone concentration were significantly reduced at all time points, with maximal effects at GD 20 where a 90% reduction in ex vivo testicular production of testosterone was noted. Anogenital distance was reduced at PND 2 and testicular weight was reduced at GD 20 and PND 2 respectively. Histopathological examination of the PND 2-testes showed increased numbers of Leydig cell hyperplasias and of multinucleated germ cells. DEHP exposure resulted in decreased testosterone, Leydig cell hyperplasia and formation of multinucleated germ cells in male fetuses and offspring.

Female rats received DEHP in the drinking water at 3.0-3.5 and 30-35 mg/kg bw/d from GD 1 to PND 21 (Arcadi et al., 1998*). Decreased pup kidney weights were observed at both doses, accompanied by histopathological findings (shrinkage of renal glomeruli with signs of glomerulonephritis, dilation of renal tubuli and light fibrosis) between weeks 0 and 4 of age. Lower testicular weights were observed, associated with severe histopathological changes which included only a few elongated spermatids in tubules showing a pervious lumen at low dose level and a generalized disorganization of the tubular epithelium with spermatogonia detached from the basal membrane, absence of elongated spermatids and spermatozoa, and with the tubular lumen filled with cellular deposits at high dose level. No NOAEL was established. There is doubt regarding the delivered dose in this experiment as DEHP is not soluble in water so was delivered as a suspension.

Data not reported in previous evaluations

Female Wistar rats were given oral (gavage) doses of DEHP at 15, 45, 135, 405, 1215 µg/kg/bw/d or 5, 15, 45, 135 and 405 mg/kg bw/d on GD6 to PND21 (Grande et al., 2006). Exposure continued through lactation. In dams, liver and kidney weights were significantly increased at the highest dose level (405 mg/kg bw/d) No other signs of maternal toxicity were evident. Litter sizes, sex ratios, postimplantation losses and numbers of viable pups were also unaffected. In offspring, a significant increase in liver weight was observed on PND1 (but not PND22) at 135 and 405 mg/kg bw/d. A significant delay in the age of vaginal opening was observed at 15 mg/kg bw/d and above. Anogenital distance and nipple development were unaffected.

In a parallel study, effects of DEHP were studied on male offspring rats from the above study (Andrade et al., 2006). Nipple retention and reduced AGD were seen in

males exposed to the highest dose (405 mg/kg bw/d). Delayed preputial separation was observed in animals exposed to 15 mg/kg bw/d and above. Testes weights were significantly increased at 5, 15, 45 and 135 mg/kg bw/d (but not 405 mg/kg bw/d) on PND 22. Histopathological examinations of testes on PND 1 and 22 showed changes at the two highest doses (135 and 405 mg/kg bw/d). On PND 1, bi- and multinucleated gonocytes were evident. On PND 22, signs of reduced germ cell differentiation in seminiferous tubules were observed. The study concluded that DEHP acts as an anti-androgen in males at the highest dose level (405 mg/kg bw/d) but also induced subtle developmental effects at lower doses.

4.8.6 Prenatal developmental toxicity studies

Previous evaluations

Dietary levels of 0, 0.025, 0.05, 0.10, or 0.15% of DEHP (0, 44, 91, 190.6, or 292.5 mg/kg bw/d) were administered to mice throughout gestation (GD 0-17) (NTIS, 1984*; Tyl et al., 1988). Reduced maternal body weight gain was noted at 0.1% and above, mainly due to reduced gravid uterine weight. Increased resorptions, late foetal deaths and malformed foetuses, and decreased foetal weight and viable foetuses were observed at 0.1% and above. Increased malformed foetuses were seen at 0.05% and above. The external malformations included unilateral and bilateral open eyes, exophthalmia, exencephaly, and short, constricted or no tail. Visceral malformations were localised predominantly in the major arteries. Skeletal defects included fused and branched ribs and misalignment and fused thoracic vertebral centra. The NOAEL for maternal toxicity was 0.05% (91 mg/kg bw/d) and for developmental toxicity was 0.025% (44 mg/kg bw/d).

Pregnant rats received DEHP by gavage at doses of 0, 40, 200, or 1000 mg/kg bw/d from GD 6 to 15 (BASF, 1995*; Hellwig et al., 1997). Reduced uterine weights and increased relative kidney and liver weights were observed in dams at 1000 mg/kg bw/d. Also at this dose, decreased viable foetuses and foetal body weights, and increased implantation loss, external and skeletal malformed foetuses (predominantly of the tail, brain, urinary tract, gonads, vertebral column, and sternum) and foetuses with soft tissue, skeletal variations and retardations were seen. The NOAEL for maternal and developmental toxicity was 200 mg/kg bw/d.

DEHP at doses of 0, 40, 200, or 1000 mg /kg bw/d was administered by gavage to pregnant mice (15/group) from GD 6 to 15 (Huntingdon, 1997*). At GD 17, decreased viable pups and increased resorptions and post-implantation loss were observed at 1000 mg/kg bw/d. Cardiovascular abnormalities, tri-lobed left lungs, fused ribs, fused thoracic vertebral centres and arches, immature livers, and kidney anomalies were also observed at this dose. At 200 mg/kg bw/d, there was a slight increase in foetuses with intra-muscular or nasal haemorrhage or dilated orbital sinuses. There also were a small number of foetuses with anomalous innominate or azygous blood vessels at this dose level. A NOAEL of 200 mg/kg bw/d was established for maternal toxicity and 40 mg/kg bw/d for developmental toxicity.

Data not reported in previous evaluations

Oral

Pregnant Sprague–Dawley rats were administered 0, 11, 33, 100, or 300 mg DEHP/kg bw/d by oral gavage starting on GD 8-18 (Calafat et al., 2006). Amniotic

fluid samples were collected from each pup in the litters at necropsy on GD 18. Concentrations of MEHP in amniotic fluid were strongly correlated with corresponding maternal DEHP doses.

Pregnant Wistar rats were gavaged from GD 7 to 21 with vehicle or 10, 30, 100 or 300 mg/kg bw/d of DEHP. Male foetuses were examined on GD 21 (Borch et al., 2006). No maternal effects were reported. Testicular testosterone production *ex vivo* and testicular testosterone levels were reduced significantly at the highest dose. Histopathological effects on gonocytes were observed at 100 and 300 mg/kg bw/d. At the highest dose level Leydig cell effects and vacuolisation of Sertoli cell were observed. There was reduced testicular mRNA expression of the steroidogenesis related factors and reduced mRNA expression of a nuclear receptor involved in regulation steroid synthesis at the two highest doses. Even at the highest dose, there was no change in PPAR α mRNA expression. The NOAEL for developmental effects was 30 mg/kg bw/d and the LOAEL was 100 mg/kg bw/d based on testicular pathology effects.

In a study of several phthalates, DEHP was administered orally to Sprague-Dawley rat dams at 750 mg/kg bw/d from GD 14 to PND 3 (Gray et al., 2000). There was no overt maternal toxicity or reduced litter sizes. DEHP treatment reduced maternal weight gain, pregnancy weight gain and pup weights. Male, but not female pups in both DEHP and BBP groups displayed shortened AGD and reduced testes weights. As infants, males had female-like areolas/nipples and increased incidence of reproductive malformations.

Inhalation

In rats, there was no consistent evidence of any treatment-related prenatal or postnatal developmental effects in the offspring of females (25/group) exposed to up to 300 mg/m³ DEHP (the highest dose tested), 6 h/d during the period of organogenesis (GD 6–15) (Merkle et al., 1988*). The number of live foetuses/dam was statistically significantly decreased and number of resorptions increased in the 50 mg/m³ group but not at the next highest dose level.

Parenteral

There are insufficient data on the developmental toxicity of DEHP administered parenterally to identify LOAELs and NOAELs for these exposure routes. In the only published intravenous exposure study, no foetal toxicity was observed following intravenous administration of DEHP to pregnant rats (Lewandowski et al., 1980*). However the doses, 1 - 5 mg/kg bw/d were lower than those used in oral exposure studies. The lowest dose reported to produce foetal toxicity following intraperitoneal (IP) administration was 1970 mg/kg bw/d (Peters & Cook, 1973*). Of 10 dams dosed on GD 3, 6, and 9 only one survived to deliver. Singh et al. (1972*) administered 5 or 10 mL/kg bw (4930 and 9860 mg/kg bw) to groups of five Sprague-Dawley rats by IP injections on GD 5, 10, and 15. Maternal toxicity was not evaluated in this study. There was an increased frequency of resorptions at both doses and a decrease in foetal weights. Gross anomalies were only observed at the 9860 mg/kg bw/d dose. The IP studies are limited as only high doses were tested and group size was small.

DEHP and MEHP were orally administered to pregnant ICR mice (9-11/group) at 0, 50, 100, 200, 400 mg/kg bw/d (MEHP) or 0, 250, 500, 1000 or 2000 mg/kg bw/d DEHP on GD 7-9 (Shiota and Mima, 1985). A second group received 0, 500, 1000,

2000, 4000, 8000 mg/kg bw/d (DEHP) or 0, 50, 100, 200 mg/kg bw/d (MEHP) by IP injections on GD 7-9. In groups given DEHP orally, resorptions and malformed foetuses (anencephaly and exencephaly) increased significantly above 500 mg/kg bw/d. No teratogenic effects were revealed following IP doses of DEHP, or oral or IP doses of MEHP, although high doses were abortifacient and lethal to pregnant females. Thus, DEHP is embryotoxic and teratogenic in mice when given orally but not by IP administration. This difference may be a result of differences in metabolism, disposition, or excretion due to the route of administration. Although MEHP is a principal metabolite of DEHP and is more toxic than DEHP to adult mice, it seems that MEHP is not teratogenic in ICR mice.

4.8.7 Mode of action

DEHP was not a competitive agonist at the oestrogen receptor (ER) in an in vitro competitive ligand-binding assay and did not induce ER-mediated gene expression in MCF-7 cells up to 10^{-5} M (Zacharewski et al., 1998). DEHP (up to 10^{-5} M) had no binding affinity for ER α or ER β in vitro (Toda et al., 2004). DEHP, but not MEHP, demonstrated weak estrogenic activities in a human ER α (but not ER β) reporter gene assay in CHO-K1 cells transfected with expression vectors for ER α , ER β and androgen receptor (AR) (Takeuchi et al., 2005). DEHP, but not MEHP, also demonstrated anti-estrogenic activity via ER β , but not antiandrogenic activity in the hAR-transactivation assay. Neither DEHP nor its metabolite MEHP displayed affinity for the human AR at concentrations up to 10^{-6} M in a reporter gene assay using COS monkey cells transfected with expression vectors for human AR (Parks et al., 2000).

DEHP (but not MEHP) increased proliferation of human breast cancer MCF-C7 cells (Okubo et al., 2003; Hong et al., 2005). However, the effects were not replicated in vivo as oral treatment with 600 mg/kg bw/d DEHP for 3 days did not increase expression of CaBP-9k mRNA (a gene highly regulated by 17 β -oestradiol) in 7 day old female SD rats (Hong et al., 2005). DEHP did not induce estrogenic responses in vivo in uterotrophic and vaginal cornification assays using immature and mature ovariectomised rats (Zacharewski et al., 1998).

DEHP (1000 mg/kg bw/d) administered orally to rat dams on GD 14-18 significantly reduced both ex vivo testosterone production and insl3 gene expression in foetal rat testes. These effects are likely to result in gubernacular malformations and cryptorchidism in rats (Wilson et al., 2004).

Conclusion

Effects on fertility

In vitro assays showed that neither DEHP nor its metabolite MEHP displayed affinity for the estrogen or androgen receptor suggesting that DEHP is not an androgen receptor antagonist, but acts as an antiandrogen.

There are very limited human data examining the reproductive effects of DEHP. These studies largely examine the relationship between urine levels of the DEHP metabolite, MEHP, and differing measurements of male and female reproductive health. The studies are small and largely negative. However, the most recent study suggests that at very high exposure levels to DBP and DEHP (mean serum MBP

644.3 µg/g creatinine; MEHP 565.7 µg/g creatinine), free testosterone levels are reduced (Pan et al., 2006).

There are many experimental animal studies, largely oral, using rats or mice. The most sensitive effects, perturbations in testicular structure and function, have been consistently observed in several reproductive toxicity studies in rats and mice by both oral and parenteral routes of exposure (NTP, 1982*; Sjoberg et al., 1985b; Lamb et al., 1987; Poon et al., 1997; David et al., 2000a, b; Akingbemi et al., 2001; Schilling et al., 2001; Cammack et al., 2003; Wolfe & Layton, 2003; Akingbemi et al., 2004). In vivo and in vitro assays have demonstrated that the Sertoli cell is the most sensitive target of toxicity, causing subsequent germ cell depletion. Rats appear to be the more sensitive species than mice for testicular effects.

Increased LH and testosterone levels in Leydig cells were observed at 10 mg/kg bw/d with no effects at 1 mg/kg bw/d in 3 week old rats exposed for 28 days (Akingbemi et al., 2001). For testicular histopathology, the NOAEL and LOAEL were 3.7 and 38 mg/kg bw/d, respectively, in 4-6 weeks old rats exposed for 90 days (Poon et al., 1997). Decreases in testicular weight were reported at higher doses. For the endpoint of fertility, a NOAEL of 14 mg/kg bw/d is derived from a continuous breeding study in adult mice (Lamb et al., 1987). The LOAEL was 140 mg/kg bw/d.

The consistent finding of testicular effects in rats and mice is in contrast to studies in marmosets (Kurata et al., 1998*; Mitsubishi-Chemical-Safety-Institute, 2003*; Tomonari et al., 2006). No treatment-related changes in testicular histology or more gross parameters were observed at the highest dose used, 2500 mg/kg bw/d.

Developmental effects

A number of human studies have attempted to link maternal MEHP levels with gestation length, onset of puberty and AGD. However, these studies, which were largely negative, are considered inadequate as they generally lacked an adequate control group and were of small sample size. Developmental studies in experimental animals comprise single and multiple-generation exposure largely by the oral route and predominantly in rodents.

There are no dermal studies, only a single inhalation study and few studies using parenteral routes of exposure. There are no developmental studies in primates.

Numerous studies have shown that DEHP is embryotoxic in rats at doses close to maternally toxic levels. In mice, several studies have shown that DEHP is embryotoxic and teratogenic at dose levels below those producing observable evidence of toxicity to the dams.

In studies where exposure was limited to gestation, mice appear to be more sensitive to the developmental toxic effects of DEHP than rats. In mice, several studies have shown that DEHP is embryotoxic and teratogenic at dose levels below those producing observable evidence of toxicity to the dams. In rats, developmental studies have shown that DEHP is embryotoxic at doses close to maternally toxic dose levels when dosing encompassed early gestation exposure. DEHP induced overt structural malformations in rats exposed to 1000 mg/kg bw/d during the critical period of development (BASF, 1995*; Hellwig et al., 1997). More subtle endpoints were not recorded in all studies. Reduced AGD was reported in a number of studies. The LOAEL was at the non-maternotoxic dose of 113 mg/kg bw/d in rats (Schilling et al., 2001). One other study reported decreased testicular weight and pathology at an

estimated dose of 30-35 mg/kg bw/d but these results are questionable as doses administered were doubtful (Arcadi et al., 1998*). In addition, data showed that DEHP disrupted male rat sexual differentiation by reducing testosterone levels (Akingbemi et al., 2001).

Developmentally induced effects are seen at lower doses in multigenerational studies. A well conducted oral 3-generational study in rats derived a NOAEL for developmental toxicity of 4.8 mg/kg bw/d based on the finding of small male reproductive organs at 14 mg/kg bw/d (Wolfe & Layton, 2003). At higher levels of exposure, effects on in utero survival, reduced AGD, undescended testes, retained nipples/areolae, incomplete preputial separation and disruption of spermatogenesis in offspring were evident. In this study, testicular abnormalities in the F1 and F2 generations were much more severe than in the F0 generation.

The critical study for developmental toxicity is considered to be Wolfe & Layton (2003). For developmental effects, the NOAEL is 100 ppm (4.8 mg/kg bw/d) and the LOAEL is 1000 ppm (14 mg/kg bw/d), based on effects on the male reproductive organs.

5. Hazard Characterisation

Toxicity data for DEHP are available for all health endpoints. For endpoints with incomplete data, information from structurally similar phthalates, where available, was used to extrapolate potential toxicity. Relevant read-across information was obtained from other NICNAS assessment reports for relevant phthalates and the NICNAS Phthalates Hazard Compendium (NICNAS, 2008), which contains a comparative analysis of toxicity endpoints across 24 phthalates, including DEHP.

DEHP is rapidly absorbed from the gastro-intestinal tract (GIT) following oral administration. Up to approximately 50% of orally administered DEHP is absorbed by the GIT system in several species including humans. In contrast, the absorption of DEHP via the skin is low. The liver, kidney, testes and blood are the main sites of distribution following orally administered DEHP. DEHP is oxidised into a large number of metabolites with MEHP and 2-EH being the main constituents. There is no evidence of accumulation in animal tissues. DEHP and metabolites are excreted in the urine and faeces. A recent human study noted that 75% of orally administered DEHP was eliminated as metabolites via urine within 2 days.

In experimental animals, DEHP exhibits low acute oral, dermal and inhalation toxicity. Intravenous and intraperitoneal administration of DEHP results in higher acute toxicity than oral or dermal administration. DEHP induced minimal skin and eye irritation in animals and did not induce skin irritation in human volunteers. Data are insufficient to determine the respiratory irritant potential of DEHP. DEHP was not a skin sensitizer in animals and limited data indicate no sensitisation reactions in humans. Human studies indicate correlations between the risk of bronchial obstruction and plasticiser-emitting components of the indoor environment. However, there is currently insufficient evidence supporting a causal relationship between respiratory effects and DEHP.

Repeat dose effects of DEHP have been evaluated in a number of animal species by several routes of exposure. The most pronounced findings were effects on the liver (hepatomegaly, peroxisome proliferation), testes (tubular atrophy) and kidneys (increased kidney weights, mineralisation of renal papilla, tubule cell pigments and chronic progressive nephropathy). For liver and kidney toxicity (increases in serum albumin, absolute and/or relative liver and kidney weights and hepatic peroxisome proliferation) a LOAEL was established from a well-conducted 104-week rat dietary study at 146.6 mg/kg bw/d. The NOAEL was 28.9 mg/kg bw/d. For testicular effects, a LOAEL was established at 37.6 mg/kg bw/d based on an increased incidence of Sertoli cell vacuolation in a 13-week rat dietary study. The NOAEL was 3.7 mg/kg bw/d. Studies of DEHP in monkeys failed to elicit the liver, kidney or testicular effects seen in rodents.

Peroxisome proliferation is observed in several animal species following administration of DEHP. Liver enlargement (hepatomegaly), hepatocyte hypertrophy and hyperplasia and proliferation of peroxisomes are recognised effects in rodents from exposure to peroxisome proliferators. In rodents, peroxisome proliferation has been shown to be mediated through the peroxisome proliferator-activated nuclear receptor alpha (PPAR α) (Ward et al., 1998; Klaunig et al., 2003). Using PPAR α -null mice, Lapinskas et al. (2005) recently showed that expression of PPAR α is necessary for both DEHP and dibutyl phthalate (DBP) induced liver enlargement and induction

of fatty acid metabolising enzymes confirming earlier knockout mouse studies of this receptor (Ward et al., 1998).

Studies conducted in patients treated with several hypolipidemic agents have provided no evidence for peroxisome proliferation or increased hepatocyte division in humans (Bentley et al., 1993*; Ashby et al., 1994*; Cattley et al., 1998*). The low levels of PPAR- α found in human liver could explain the low sensitivity of the human liver to the hepatotoxic effects of peroxisome proliferators (Tugwood et al., 1996*; Palmer et al., 1998*; Woodyatt et al., 1999*). Given also the minimal effects with DEHP in non-human primates, a similar low sensitivity of humans to the peroxisome proliferative effects of DEHP is therefore expected.

On a weight-of-evidence basis, DEHP is considered to be non-genotoxic. In carcinogenicity studies, DEHP showed positive transforming potential in some but not all mammalian cell transformation assays in vitro. In vivo, DEHP caused an increase in the incidence of liver tumour with a dose-response relationship in rats and mice of both sexes, and an increase in the incidence of Leydig cell tumours and MCL in male rats. DEHP-induced hepatocellular carcinomas are unlikely to be of relevance to humans since the hepatotoxic effects of DEHP, including hepatocellular tumour induction, are associated with peroxisome proliferation to which humans appear less sensitive.

Leydig-cell tumours were only reported in one animal study. Cook et al. (1999) noted similarities in the hypothalamo-pituitary-testis axis between rats and humans and concluded that substances that induce Leydig cell tumours via disruption of this axis in rats may have similar effects in humans albeit with a likely reduced Leydig cell proliferative response. An increased incidence of mononuclear cell leukaemia (MCL) was only seen in one of two rat studies and in neither of two mouse studies. This tumour type is well known to occur spontaneously, with a high incidence in the rat strain used in the study. It also has no comparable tumour type in humans (Caldwell, 1999) and so is unlikely to be relevant to humans.

The critical effects for DEHP are considered to be reproductive and developmental effects in males. Testicular toxicity appears to be the most sensitive toxicity endpoint but is significantly influenced by the age at exposure. Developing and prepubertal rats have been found to be much more sensitive to exposure to DEHP than adults. The younger animals responded to a much lower dose or produced a more serious lesion with a comparable dose on a mg/kg bw/d basis.

For effects on fertility, the NOAEL was 14 mg/kg bw/d based on a continuous breeding study in mice (Lamb et al., 1987). The LOAEL in this study was 140 mg/kg bw/d, not necessarily linked to male infertility as both sexes were exposed to DEHP in the diet. A crossover study at the highest dose indicated both males and females had reduced fertility.

A number of key studies exposed animals during gestation and/or early postnatal life (Poon et al., 1987; Akingbemi et al., 2001; Wolfe & Layton, 2003; Andrade et al., 2006). The critical study for developmental toxicity was Wolfe & Layton (2003) for testicular effects during prenatal and neonatal development with a NOAEL of 4.8 mg/kg bw/d and a LOAEL of 14 mg/kg bw/d.

Page intentionally blank for double-sided printing.

6. Human Health Hazard Summary Table

| Phthalate | Acute Toxicity | Irritation & Sensitisation | Repeated Dose Toxicity | Genetic Toxicity | Carcinogenicity | Fertility | Developmental Toxicity |
|-------------------------------|--|---|---|--|---|---|--|
| Diethylhexyl phthalate (DEHP) | <p>Oral Rat: LD50 = 30600 to > 40000 mg/kg bw</p> <p>Dermal Rabbit: LD50 = 24750 mg/kg bw</p> <p>Inhalation Rat: LC50 > 10.62 mg/L</p> | <p>Skin Irritation: Minimal effect</p> <p>Eye Irritation: Minimal effect</p> <p>Respiratory Irritation: Insufficient data</p> <p>Skin Sensitisation: Negative</p> | <p><u>Liver</u> Oral Rat: NOAEL = 28.9 mg/kg bw/d LOAEL = 146.6 mg/kg bw/d: ↑ serum albumin, ↑ liver wt and peroxisome proliferation</p> <p><u>Kidney</u> Oral Rat: NOAEL = 28.9 mg/kg bw/d LOAEL = 146.6 mg/kg bw/d: ↑ kidney weight</p> <p><u>Testes</u> Oral Rat: NOAEL = 3.7 mg/kg bw/d LOAEL = 37.6 mg/kg bw/d: Sertoli cell vacuolation</p> <p>High doses: hepatomegaly; PP; testicular tubular atrophy; renal papilla mineralisation, tubule cell pigmentation and chronic progressive nephropathy</p> | <p><i>In vitro</i> Bacterial and fungal mutation assays: negative</p> <p>Mammalian cell mutation assays: negative</p> <p><i>In vivo</i> Chromosome aberration and DNA damage assays: negative</p> <p>Chromosome aberrations in sampled human lymphocytes: negative</p> | <p><i>In vivo</i> Rat (F344), 2 year dietary study: NOAEL = 28.9 mg/kg bw/d LOAEL = 146.6 mg/kg bw/d: ↑ hepatocellular tumours and mononuclear cell leukaemia.</p> <p>Rat (male, Sprague-Dawley), lifetime (~ 3 year) dietary study: ↑ hepatocellular adenomas and carcinomas; ↑ benign Leydig cell tumors.</p> <p>Mouse (B6C3F1), 2 year dietary study: NOAEL = 98 mg/kg bw/d LOAEL = 292 mg/kg bw/d: ↑ hepatocellular adenomas and carcinomas.</p> <p>Syrian golden hamster, 23 month inhalation study: no sig. ↑ in tumour incidence</p> | <p>Continuous breeding study Mouse: NOAEL = 14 mg/kg bw/d LOAEL = 140 mg/kg bw/d: ↓ fertility</p> | <p>Multigenerational study Rat: NOAEL = 4.8 mg/kg bw/d LOAEL = 14 mg/kg bw/d: ↓ testes wt; seminiferous tubule atrophy</p> |

Page intentionally blank for double-sided printing.

References

- Agarwal D, Eustis S, Lamb IV J, Jameson C, & Kluwe W (1986a) Influence of dietary zinc on di(2-ethylhexyl) phthalate-induced testicular atrophy and zinc depletion in adult rats. *Toxicol. Appl. Pharmacol.*, 84: 12-24.
- Agarwal DK, Eustis S, Lamb JCIV, Reel JR, & Kluwe WM (1986b) Effects of di(2-ethylhexyl) phthalate on the gonadal pathophysiology, sperm morphology, and reproductive performance of male rats. *Environmental Health Perspectives*, 65: 343-50.
- Akingbemi B, Youker R, Sottas C, Ge R, Katz E, Klinefelter G, Zirkin B, & Hardy M (2001) Modulation of rat Leydig cell steroidogenic function by di(2-ethylhexyl)phthalate. *Biology of Reproduction*, 65(4): 1252-1259.
- Akingbemi B, Ge R, Klinefelter G, Zirkin B, & Hardy M (2004) Phthalate-induced Leydig cell hyperplasia is associated with multiple endocrine disturbances. *Proceedings of the National Academy of Sciences of the United States of America*, 101(3): 775-780.
- Albro PW (1986) Absorption, metabolism, and excretion of di(2-ethylhexyl) phthalate by rats and mice. *Environ. Health Perspect.* 65: 293-298
- Albro P, Corbett J, Schroeder J, Jordan S, & Matthews H (1982) Pharmacokinetics, interactions with macromolecules and species differences in metabolism of DEHP. *Environmental Health Perspectives*, 45: 19-25.
- Andrade AJM, Grande SW, Talsness CE, Grote K, Golombiewski A, Sterner-Kock A, & Chahoud I (2006) A dose response study following in utero and lactational exposure to di-(2-ethylhexyl) phthalate (DEHP): Effects on androgenic status, developmental landmarks and testicular histology in male offspring rats. *Toxicology*, 225:64-74.
- Arcadi F, Costa C, Imperatore C, Marchese A, Rapidisarda A, Salemi M, Trimarchi GR, & Costa G (1998) Oral toxicity of bis(2-ethylhexyl) phthalate during pregnancy and suckling in Long-Evans rat. *Food Chem. Toxicol.* 36: 963-970.
- Ashby J, Brady A, Elcombe C, Elliott B, Ishmael J, Odum J, Tugwood J, Kettle S, & Purchase I (1994) Mechanistically-based human hazard assessment of peroxisome proliferator induced hepatocarcinogenesis. *Human & Experimental Toxicology*, 13(Supp. 2): 1-117.
- Astill BD (1989) Metabolism of DEHP: Effects of prefeeding and dose variation, and comparative studies in rodents and the Cynomolgus monkey (CMS studies). *Drug Metab. Rev.* 21:35-53
- ATSDR (2002) Toxicological profile for di(2-ethylhexyl)phthalate. Agency for Toxic Substances and Disease Registry. U.S. Department of Health and Human Services. Public Health Service.
- Barber E, Astill B, Moran E, Schneider B, Gray T, Lake B, & Evans J (1987) Peroxisome induction studies on seven phthalate esters. *Toxicol. Ind. Health*, 3: 7-24.
- Barber ED, Teetsel NM, Kolberg KF, & Guest D (1992) A comparative study of the rates of in vitro percutaneous absorption of eight chemicals using rat and human skin. *Fundamental and Applied Toxicology*, 19:493-497.
- BASF (1986) Report on the acute dermal irritation/corrosivity to the intact dorsal skin of the White rabbit based on OECD; Report on the acute irritation to the eye of the White rabbit based on OECD., BASF: Dept. of toxicology, unpublished results.

- BASF (1990) Bestimmung der Algentoxizität. Labor für Oekologie. Unpublished report (in German).
- BASF (1995) Unpublished results (91/124), 09-28-95. BASF: Dept. of Toxicology.
- Baxter Healthcare Corporation (2000) Histopathological evaluation of testes from neonatal male rats and rabbits treated with saline or approximately 62 mg/kg di-(2-ethylhexyl)phthalate (DEHP) in 4% bovine serum albumin (BSA) during postnatal days 3-21 (Rats) or 14-42 (Rabbits).
- Bentley P, Calder I, Elcombe C, Grasso P, Stringer D, & Wiegand H-J (1993) Hepatic peroxisome proliferation in rodents and its significance for humans. *Food Chem Toxicol*, 31(11): 857-907.
- BIBRA (1990) An investigation of the effect of di-(2-ethylhexyl) phthalate (DEHP) on rat hepatic peroxisomes.
- Borch J, Dalgaard M, & Ladefoged O (2005) Early testicular effects in rats perinatally exposed to DEHP in combination with DEHA--apoptosis assessment and immunohistochemical studies. *Reproductive Toxicology*, 19(4): 517-25.
- Borch J, Metzдорff SB, Vinggaard AM, Brokken L, & Dalgaard M (2006) Mechanisms underlying the antiandrogenic effects of diethylhexyl phthalate in fetal rat testis. *Toxicology*, 223:144-155.
- Calafat AM, Brock JW, J. SM, Gray LE, Reidy JA, Barr DB, & Needham LL (2006) Urinary and amniotic fluid levels of phthalate monoesters in rats after the oral administration of di(2-ethylhexyl) phthalate and di-n-butyl phthalate. *Toxicology*, 217(1): 22-30.
- Caldwell DJ (1999b) Review of mononuclear cell leukemia in F-344 rat bioassays and its significance to human cancer risk: A case study using alkyl phthalates. *Reg. Toxicol. Pharm.* 30: 45-53.
- Cammack J, White R, Gordon D, Gass J, Hecker L, Conine D, Bruen U, Friedman M, Echols C, Yeh T, & Wilson D (2003) Evaluation of reproductive development following intravenous and oral exposure to DEHP in male neonatal rats. *International Journal of Toxicology*, 22(3): 159-174.
- Cattley R, DeLuca J, Elcombe C, Fenner-Crisp P, Lake B, Marsman D, Pastoor T, Popp J, Robinson D, Schwetz B, Tuggwood J, & Wahli W (1998) Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans? *Regul Toxicol Pharmacol*, 27: 47-60
- CEFIC (1982) Report to CEFIC on a 28 day dose and time response study of di(2-ethylhexyl) phthalate in rats, unpublished results, Univ. of Surrey, Robens Institute of Industrial and Environmental Health and Safety.
- CERHR (2005) NTP-CERHR Expert panel update on the reproductive and developmental toxicity of di (2-ethylhexyl) phthlate. Centre for the Evaluation of Risks to Human Reproduction. Expert Panel National Toxicology Program, U.S Department of Health and Human Services.
- Chu I, Dick D, Bronaugh R, & Tryohonas L (1996) Skin reservoir formation and bioavailability of dermally administered chemicals in hairless guinea pigs. *Fd. Chem. Toxic.* 34: 267-276.
- Clark K, Cousins I, & Mackay D (2003) Assessment of critical exposure pathways. In: Staples C ed. *The Handbook of Environmental Chemistry*. New York., Springer-Verlag. 227-262.
- CMA (1982) Toxicological effects of di(2-ethylhexyl) phthalate., Chemical Manufacturers Assoc.

- CMA (1984) A 21 day dose-relationship study of di(2-ethylhexyl) phthalate in rats., Chemical Manufacturers Association.
- Cobellis L, Latini G, DeFelice C, Razzi S, Paris I, Ruggieri F, Mazzeo P, & Petraglia F (2003) High plasma concentrations of di-(2-ethylhexyl)-phthalate in women with endometriosis. *Human Reproduction*, 18(7): 1512-1515.
- Colon I, Caro D, Bourdony CJ, & Rosario O (2000) Identification of phthalate esters in the serum of young Puerto Rican girls with premature breast development. *Environmental Health Perspectives*, 108(9): 895-900.
- Conway J, Tomaszewski K, Olson M, Cattley R, Marsman D, & Popp J (1989) Relationship of oxidative damage to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl) phthalate and Wy-14643. *Carcinogenesis*, 10: 513-519.
- Cook JC, Klinefelter GR, Hardisty JF, Sharpe RM & Foster PMD (1999) Rodent Leydig cell tumorigenesis: a review of the physiology, pathology, mechanisms, and relevance to humans. *Crit. Rev. Toxicol.* 29: 169-261.
- Crocker J, Safe S, & Acott P (1988) Effects of chronic phthalate exposure on the kidney. *Journal of Toxicology and Environmental Health*, 23(4): 433-444.
- Curto KA & Thomas JA (1982) Comparative effects of diethylhexyl phthalate or monoethylhexyl phthalate on male mouse and rat reproductive organs. *Toxicology and Applied Pharmacology*, 62(1): 121-125.
- Dalsenter P, Santana G, Grande S, Andrade A, & Araujo S (2006) Phthalate affect the reproductive function and sexual behavior of male Wistar rats. *Human & Experimental Toxicology*, 25: 297-303.
- David R, Moore M, Finney D, & Guest D (2000a) Chronic toxicity of di(2-ethylhexyl)phthalate in rats. *Toxicological Sciences*, 55(2): 433-443.
- David RM, Moore M, Finney D, & Guest D (2000b) Chronic toxicity of di(2-ethylhexyl)phthalate in mice. *Toxicological Sciences*, 58(2): 377-385.
- Deisinger P, Perry L, & Guest D (1998) In Vivo Percutaneous Absorption of [¹⁴C]DEHP from [¹⁴C]DEHP-plasticized Polyvinyl Chloride Film in Male Fischer 344 rats. *Food and Chemical Toxicology* 36: 521-527.
- Dirven, H.A.A.M., van den Broek, P.H.H., Arends, A.M.M., Nordkamp, H.H., de Lepper, A.J.G.M., Henderson, P.Th., & Jongeneelen, F.J. (1993a) Metabolites of the plasticizer di-(2-ethylhexyl) phthalate in urine samples of workers in polyvinylchloride processing industries. *Int. Arch. Occup. Environ. Health*, 64: 549-554.
- Dirven, HAAM, van den Broek, PHH, & Jongeneelen, FJ (1993b). Determination of four metabolites of the plasticizer di-(2-ethylhexyl) phthalate in human urine samples. *Int. Arch. Occup. Environ. Health*, 64: 555-560.
- Doelman C, Borm P, & Bast A (1990) Plasticisers, another burden for asthmatics? *Agents and Actions*, 31: 81-84.
- Dostal L, Jenkins W, & Schwetz B (1987a) Hepatic peroxisome proliferation and hypolipidemic effects of di(2-ethylhexyl) phthalate in neonatal and adult rats. *Toxicol. Appl. Pharmacol.*, 87: 81-90.
- Dostal L, Weaver R, & Schwetz B (1987b) Transfer of di(2-ethylhexyl) phthalate through rat milk and effects on milk composition and the mammary gland. *Toxicol. Appl. Pharmacol.*, 91: 315-325.
- Dostal L, Chapin R, Stefanski S, Harris M, & Schwetz B (1988) Testicular toxicity and reduced Sertoli cell numbers in neonatal rats by di(2 ethylhexyl) phthalate and the recovery of fertility as adults. *Toxicol. Appl. Pharmacol.*, 95: 104-121.

- Duty S, Singh N, Silva M, Barr D, Brock J, Ryan L, Herrick R, Christiani D, & Hauser R (2003a) The relationship between environmental exposures to phthalates and DNA damage in human sperm using the neutral comet assay. *Environ Health Perspect*, 111: 1164-9.
- Duty SM, Silva MJ, Barr DB, Brock JW, Ryan L, Chen Z, Herrick RF, Christiani DC, & Hauser R (2003b) Phthalate exposure and human semen parameters. *Epidemiology*, 14: 269-277.
- Duty SM, Calafat AM, Silva MJ, Brock JW, Ryan L, Chen Z, Overstreet J, & Hauser R (2004) The relationship between environmental exposure to phthalates and computer-aided sperm analysis motion parameters. *Journal of Andrology*, 25(2): 293-302.
- Duty S, Calafat A, Silva M, Ryan L, & Hauser R (2005) Phthalate exposure and reproductive hormones in adult men. *Hum Reprod*, 20: 604-10.
- Eastman Kodak (1992a) A subchronic (4-week) dietary oral toxicity study of di(2-ethylhexyl) phthalate in B6C3F1 mice (final report), Eastman Kodak Co.
- Eastman Kodak (1992b) A subchronic (13-week) dietary oral toxicity study of di(2-ethylhexyl) phthalate in Fischer 344 rats (final report), Eastman Kodak Co.
- ECB (2006) Bis (2-Ethylhexyl) Phthalate Risk Assessment, Draft of March 2006. European Communities, European Chemicals Bureau.
- Elsisi A, Carter D, & Sipes I (1989) Dermal absorption of phthalate diesters in rats. *Fundam. Appl. Toxicol.* 12: 70-77.
- EPA (1989) NHATS broad scan analysis: Population estimates from fiscal year 1982 specimens. Washington, DC: US Environmental Protection Agency, Office of Toxic Substances, EPA 569/5-90-001
- Exxon (1982) One-week prechronic oral feeding study in F-344 rats. Pathology report., Exxon Chemicals Americas.
- Exxon (1994) Jayflex DEHP. Skin sensitisation in the Guinea-pig. Huntingdon Research Centre Ltd., Cambridgeshire (England), unpublished results. Bruxelles (Belgium), Exxon Chemical Int. Inc.
- FDA (2002) Safety assessment of di(2-ethylhexyl)phthalate (DEHP) released from PVC medical devices. Food and Drug Administration Center for Devices and Radiological Health.
- Fukuhara M & Takabatake E (1977) Studies on the liver enlargement induced by dietary administration of di-(2-ethylhexyl) phthalate (DEHP). *J. Toxicol. Sci.*, 2: 11-23.
- Furtmann K (1996) Phthalates in the aquatic environment. English translation of the ECPI./CEFIC report 6/93.
- Ganning A, Brunk U, Edlund C, Elhammer Å, & Dallner G (1987) Effects of prolonged administration of phthalate esters on the liver. *Environ. Health Perspect.*, 73: 251-258.
- Ganning A, Olsson M, Brunk U, & Dallner G (1990) Effects of prolonged treatment with phthalate ester on rat liver. *Pharmacol. Toxicol.*, 68: 392-401.
- General Motors (1982a) Disposition of di(2-ethylhexyl) phthalate following inhalation and peroral exposure in rats. TSCATS: OTS0530339, Doc. ID.: 86-910000683, 06-22-82, General Motors Corp.
- General Motors (1982b) Disposition of di(2-ethylhexyl) phthalate following inhalation and peroral exposure in rats. TSCATS: OTS84003A, Doc. ID.: 878210878, 07-27-82, General Motors Corp.

- Gilioli R, Bulgheroni C, Terrana T, Filippini G, Massetto N, & Boeri R (1978) Horizontal and longitudinal study of a population employed in the production of phthalates. *Med. Lav.*, 69: 620-631.
- Grande SW, Andrade AJ, Talsness CE, Grote K, & Chahoud I (2006) A dose response study following in utero and lactational exposure to di-(2-ethylhexyl) phthalate (DEHP): Effects on female rat reproductive development. *Toxicol Sci.*, 91: 247-254.
- Gray LEJ, Ostby J, Furr J, Price M, Veeramachaneni D, & Parks L (2000) Perinatal exposure to the phthalates DEHP, BBP, and DINP, but not DEP, DMP, or DOTP, alters sexual differentiation of the male rat. *Toxicological Sciences*, 58(2): 350-365.
- Gray T, Butterworth K, Gaunt L, Grasso P, & Gangolli S (1977) Short-term toxicity study of di(2-ethylhexyl) phthalate in rats. *Fd. Cosmet. Toxicol.*, 15: 389-399.
- Greener Y, Gillies B, Wienckowski D, Schmitt D, Woods E, & Youkilis E (1987) Assessment of the safety of chemicals administered intravenously in the neonatal rat. *Teratology*, 35: 187-194.
- Hardell L, Ohlson C-G, & Fredrikson M (1997) Occupational exposure to polyvinyl chloride as a risk factor for testicular cancer evaluated in a case-control study. *Int. J. Cancer*, 73: 828-830.
- Hardell L, Malmqvist N, Ohlson C, Westberg H, & Eriksson M (2004) Testicular cancer and occupational exposure to polyvinyl chloride plastics: A case-control study. *International Journal of Cancer*, 109(3): 425-429.
- Hazleton (1983) Screening of priority chemicals for potential reproductive hazard, Centers for disease control, Hazleton Laboratories.
- Health Canada (2002) DEHP in Medical Devices: An Exposure and Toxicity Assessment, Medical Devices Bureau, Therapeutic Products Directorate, Health Products & Foods Branch, Health Canada.
- Hellwig J, Freudenberger H, & Jäckh R (1997) Differential prenatal toxicity of branched phthalate esters in rats. *Fd. Chem. Toxicol.*, 35: 501-512.
- Hodgson J (1987) Results of peroxisome induction studies on tri(2-ethylhexyl) trimellitate and 2-ethylhexanol. *Toxicol. Ind. Health*, 3: 49-60.
- Hong E, Ji YK, Choi KC, Manabe N, & Jeung EB (2005) Conflict of estrogenic activity by various phthalates between in vitro and in vivo models related to the expression of Calbindin-D-9k. *Journal of Reproduction & Development*, 51(2): 253-263.
- Hüls A (1981) Safety tests on Vestinol AH di-2-ethylhexylphthalate.
- Hüls A (1987) Prüfung der akuten Augen- und Schleimhautreizwirkung von VESTINOL AH.
- Hüls A (1997) Personal communication with B. Mentzel, Hüls, 16th Januari 1997.
- Huntingdon H-A (1997) Phthalic acid, di(2-ethylhexyl) ester (DEHP): Study of embryo-foetal toxicity in the CD-1 mouse by oral gavage administration, Huntingdon.
- IARC (2000) IARC monographs on the evaluation of carcinogenic risks to humans. Some industrial chemicals. World Health Organisation, International Agency for Research on Cancer.
- ICI (1982) Di(2-ethylhexyl) phthalate: a comparative subacute toxicity study in the rat and marmoset., ICI Americas Inc.
- Ito Y, Yokota H, Wang R, Yamanoshita O, Ichihara G, Wang H, Kurata Y, Takagi K, & Nakajima T (2005) Species differences in the metabolism of di(2-ethylhexyl) phthalate (DEHP) in several organs of mice, rats, and marmosets. *Archives of Toxicology*, 79(3): 147-54.

- Jaakkola J, Oie L, Nafstad P, Botten G, Samuelsen S, & Magnus P (1999) Interior surface materials in the home and the development of bronchial obstruction in young children in Oslo, Norway. *American Journal of Public Health*, 89(2): 188-192.
- Jacobson M, Kevy S, & Grand R (1977) Effects of a plasticizer leached from polyvinyl chloride on the subhuman primate: a consequence of chronic transfusion therapy. *J Lab Clin Med*, 89(5): 1066-79.
- Jarfelt K, Dalgaard M, Hass U, Borch J, Jacobsen H, & Ladefoged O (2005) Antiandrogenic effects in male rats perinatally exposed to a mixture of di(2-ethylhexyl) phthalate and di(2-ethylhexyl) adipate. *Reproductive Toxicology*, 19(4): 505-15.
- Jonsson B, Richthoff J, Rylander L, Giwercman A, & Hagmar L (2005) Urinary phthalate metabolites and biomarkers of reproductive function in young men. *Epidemiology*, 16(4): 487-493.
- Khaliq M & Srivastava S (1993) Induction of hepatic polyamines by di(2-ethylhexyl) phthalate in rats. *Toxicology Letters*, 66: 317-321.
- Klaunig JE, Babich MA, Baetcke KP, Cook JC, Corton JC, David RM, Deluca JG, Lai DY, McKee RH, Peters JM, Roberts RA & Fenner-Crisp PA (2003) PPAR alpha agonist-induced rodent tumours: modes of action and human relevance. *Crit. Rev. Toxicol.* 33: 655-780
- Klimisch HJ, Gamer AO, Hellwig J, Kaufmann W, & Jackh R (1992) Di-(2-ethylhexyl) phthalate: a short-term repeated inhalation toxicity study including fertility assessment. *Food & Chemical Toxicology*, 30(11): 915-919.
- Kluwe W, Haseman J, Douglas J, & Huff J (1982) The carcinogenicity of dietary di-(2-ethylhexyl) phthalate (DEHP) in Fischer 344 rats and B6C3F1 mice. *J. Toxicol. Environ. Health*, 10: 797-815.
- Kluwe W, Haseman J, & Huff J (1983) The carcinogenicity of di-(2-ethylhexyl) phthalate (DEHP) in perspective. *J. Toxicol. Environ. Health*, 12: 159-169.
- Koch HM, Bolt HM & Preuss R (2005) New metabolites of di(2-ethylhexyl)phthalate (DEHP) in human urine and serum after single oral doses of deuterium-labelled DEHP. *Arch. Toxicol.* 79:367-376
- Krauskopf L (1973) Studies on the toxicity of phthalates via ingestion. *Environ. Health Perspect*, 3: 61-72.
- Kroschwitz J (1998) Kirk-Othmer Encyclopedia of Chemical Technology. New York, John Wiley and Sons.
- Kurahashi N, Kondo T, Omura M, Umemura T, Ma M, & Kishi R (2005) The effects of subacute inhalation of di (2-ethylhexyl) phthalate (DEHP) on the testes of prepubertal Wistar rats. *Journal of Occupational Health*, 47(5): 437-44.
- Kurata Y, Kidachi F, Yokoyama M, Toyota N, Tsuchitani M, & Katoh M (1998) Subchronic toxicity of di(2-ethylhexyl)phthalate in common marmosets: lack of hepatic peroxisome proliferation, testicular atrophy, or pancreatic acinar cell hyperplasia. *Toxicol. Sci.*, 42: 49-56.
- Lake B, Gray T, Foster J, Stubberfield C, & Gangolli S (1984a) Comparative studies on di-(2-ethylhexyl) phthalate-induced hepatic peroxisome proliferation in the rat and hamster. *Toxicol. Appl. Pharmacol.*, 72: 46-60.
- Lake B, Rijcken R, Gray T, Foster J, & Gangolli S (1984b) Comparative studies of the hepatic effects of di- and mono-n-octyl phthalates, di(2-ethylhexyl) phthalate and clofibrate in the rat. *Acta Pharmacol. Toxicol.*, 54: 167-176.

- Lake B, Kozlen S, Evans J, Gray T, Young P, & Gangolli S (1987) Effect of prolonged administration of clofibrilic acid and di(2-ethylhexyl) phthalate on hepatic enzyme activities and lipid peroxidation in the rat. *Toxicology*, 44: 213-228.
- Lamb J, Chapin R, Teague J, Lawton A, & Reel J (1987) Reproductive effects of four phthalic acid esters in the mouse. *Toxicology and Applied Pharmacology*, 88(2): 255-69.
- Lapinskas PJ, Brown S, Leesnitzer LM, Blanchard S, Swanson C, Cattley RC, & Corton JC (2005) Role of PPAR alpha in mediating the effects of phthalates and metabolites in the liver. *Toxicology*, 207: 149-163
- Latini G, De Felice C, Presta G, Del Vecchio A, Paris I, Ruggieri F, & Mazzeo P (2003) In utero exposure to di-(2-ethylhexyl)phthalate and duration of human pregnancy. *Environmental Health Perspectives*, 111(14): 1783-1785.
- Lawrence W, Malik M, Turner J, Singh A, & Autian J (1975) A toxicological investigation of some acute, short-term, and chronic effects of administering di-2-ethylhexyl phthalate (DEHP) and other phthalate esters. *Environ. Res.*, 9: 1-11.
- Leber H & Uviss T (1979) Influence of the plasticiser di-2-ethylhexyl-phthalate on drug metabolising enzymes in the liver of uraemic rats. *Proc Eur Dial Transplant Assoc*, 16: 232-237.
- Lewandowski M, Fernandes J, & Chen T (1980) Assessment of the teratogenic potential of plasma-soluble extracts of diethylhexyl phthalate-plasticized poly(vinyl chloride) plastics in rats. *Toxicology and Applied Pharmacology*, 54(1): 141-147.
- Li LH, Jester WF, Laslett AL, & Orth JM (2000) A single dose of di-(2-ethylhexyl) phthalate in neonatal rats alters gonocytes, reduces Sertoli cell proliferation, and decreases cyclin D2 expression. *Toxicology & Applied Pharmacology*, 166(3): 222-229.
- Lindgren A, Lindquist NG, Lyden A, Olsson T, & Ullberg S (1982) A whole body autoradiographic study on the distribution of ¹⁴C-labelled di-(2-ethylhexyl)phthalate in mice. *Toxicology* 23: 149-158.
- Liss, G. M., Albro, P.W., Hartle, R.W., and Stringer W.T. (1985). Urine phthalate determinations as an index of occupational exposure to phthalic anhydride and di-(2-ethylhexyl) phthalate. *Scand. J. Work Environ. Health*, 11: 381-387.
- Main KM, Mortensen GK, Kaleva MM, Boisen KA, Damgaard IN, Chellakooty M, Schmidt IM, Suomi AM, Virtanen HE, Petersen JH, Andersson AM, Toppari J, & Skakkebaek NE (2006) Human breast milk contamination with phthalates and alterations of endogenous reproductive hormones in infants three months of age. *Environmental Health Perspectives*, 114(2): 270-276.
- Mangham B, Foster J, & Lake B (1981) Comparison of the hepatic and testicular effects of orally administered di(2-ethylhexyl) phthalate and dialkyl 79 phthalate in rat. *Toxicol. Appl. Pharmacol.*, 61: 205-214.
- Mann A, Price S, Mitchell F, Grasso P, Hinton R, & Bridges J (1984) Comparison of the short-term effects of di-(2-ethylhexyl) phthalate, di(n-hexyl) phthalate and di(noctyl) phthalate in rats. *Toxicol. Appl. Pharmacol.*, 77: 116-132.
- McEwen GJ & Renner G (2006) Validity of anogenital distance as a marker of in utero phthalate exposure. *Environmental Health Perspectives*, 114(1): A19-20.
- McKee R, Butala J, David R, & Gans G (2004) NTP center for the evaluation of risks to human reproduction reports on phthalates: addressing the data gaps. *Reproductive Toxicology*, 18(1): 1-22.
- Melnick RL, Morrissey RE, & Tomaszewski KE (1987) Studies by the National Toxicology Program on bis(2-ethylhexyl) phthalate. *Toxicology and Industrial Health*, 3(2): 99-118.

- Merkle J, Klimisch HJ, & Jackh R (1988) Developmental toxicity in rats after inhalation exposure of di-2-ethylhexylphthalate (DEHP). *Toxicology Letters*, 42(2): 215-223.
- Milkov L, Aldyreva M, Popova T, Lopukhova K, Makarenko Y, Malyar L, & Shakhova T (1973) Health status of workers exposed to phthalate plasticizers in the manufacture of artificial leather and films based on PVC resins. *Environ. Health Perspect.*, 3: 175-178.
- Mitchell F, Price S, Hinton R, Grasso P, & Bridges J (1985) Time and dose-response study of the effects on rats of the plasticizer di-(2-ethylhexyl) phthalate. *Toxicol. Appl. Pharmacol.*, 81: 371-392.
- Mitsubishi-Chemical-Safety-Institute (2003) Sixty-five week repeated oral dose toxicity study of di(2-ethylhexyl)phthalate (DEHP) in juvenile common marmosets. Ibaraki, Japan, Mitsubishi Chemical Safety Institute.
- Miyazawa S, Furuta S, Osumi T, & Hashimoto T (1980) Turnover of enzymes of peroxisomal α -oxidation in rat liver. *Biochim. Biophys. Acta*, 630: 367-374.
- Modigh C, Bodin S, Lillienberg L, Dahlman-Hoglund A, Akesson B, & Axelsson G (2002) Time to pregnancy among partners of men exposed to di(2-ethylhexyl)phthalate. *Scandinavian Journal of Work Environment & Health*, 28(6): 418-428.
- Moody D & Reddy J (1978) Hepatic peroxisome (microbody) proliferation in rats fed plasticizers and related compounds. *Toxicol. Appl. Pharmacol.*, 45: 497-504.
- Moore M (1996) Oncogenicity study in rats with Di (2-ethylhexyl)phthalate including ancillary hepatocellular proliferation and biochemical analyses, Corning Hazleton Incorporated (CHV), 9200 Leesburg Pike, Vienna, Virginia 22182-1699. Sponsor: Eastman Chemical Company, First America Center, P.O. Box 1994 Kingsport, Tennessee 37662-5394.
- Moore M (1997) Oncogenicity study in mice with Di (2-ethylhexyl)phthalate including ancillary hepatocellular proliferation and biochemical analyses, Corning Hazleton Incorporated (CHV), 9200 Leesburg Pike, Vienna, Virginia 22182-1699. Sponsor: Eastman Chemical Company, First America Center, P.O. Box 1994 Kingsport, Tennessee 37662-5394.
- Moore R, Rudy T, Lin T-M, Ko K, & Peterson R (2001) Abnormalities of sexual development in male rats with in utero and lactational exposure to the antiandrogenic plasticizer Di(2-ethylhexyl) phthalate. *Environmental Health Perspectives*, 109(3): 229-237.
- Nair KGP, Deepadevi KV, Arun P, Kumar VM, Santhosh A, Lekshmi LR, & Kurup PA (1998) Toxic effect of systemic administration of low doses of the plasticizer di-(2-ethyl hexyl) phthalate [DEHP] in rats. *Indian Journal of Experimental Biology*, 36(3): 264-272.
- Ng KME, Chu I, Bronaugh R., Franklin CA, & Somers DA (1992) Percutaneous absorption and metabolism of pyrene, benzo[a]pyrene, and di-(2-ethylhexyl) phthalate: Comparison of in vitro and in vivo results in the hairless guinea pig. *Toxicol. Appl. Pharmacol.* 115: 216-223.
- NICNAS (2008) Phthalates hazard compendium: a summary of physicochemical and human health hazard data for 24 *ortho*-phthalate chemicals. Sydney, National Industrial Chemicals Notification and Assessment Scheme.
- Nielsen J, Åkesson B, & Skerfving S (1985) Phthalate ester exposure- air levels and health of workers processing polyvinylchloride. *Am. Ind. Hyg. Assoc. J.*, 46(11): 643-647.
- NTIS (National Technical Information Service) (1984) Teratologic evaluation of diethylhexyl phthalate (CAS No. 117-81-7) in CD-1 mice.
- NTP (1982) Carcinogenesis bioassay of di(2-ethylhexyl) phthalate in F344 rats and B6C3F1 mice (feed study): National Toxicology Program 01-82.

- Nuodex (1981a) Acute oral toxicity study in rats of TCI compounds: R-1268, R-1272, R-1286 and R-1287.
- Nuodex (1981b) Dominant lethal study of three compounds: R1213, R-1214 and R-1217., Nuodex Inc.
- Nuodex (1981c) Repeated dose 28-day toxicity study with rodents. Unpublished study., Nuodex Inc.
- Oie L, Hersoug LG, & Madsen JO (1997) Residential exposure to plasticizers and its possible role in the pathogenesis of asthma. *Environmental Health Perspectives*, 105(9): 972-978.
- Okubo T, Suzuki T, Yokoyama Y, Kano K, & Kano I (2003) Estimation of estrogenic and anti-estrogenic activities of some phthalate diesters and monoesters by MCF-7 cell proliferation assay in vitro. *Biol Pharm Bull*, 26(8): 1219-1224.
- Palmer C, Hsu M, Griffin K, Raucy J, & Johnson E (1998) Peroxisome proliferator activated receptor-alpha expression in human liver. *Molecular Pharmacology*, 53(1): 14-22.
- Pan G, Hanaoka T, Yoshimura M, Zhang S, Wang P, Tsukino H, Inoue K, Nakazawa H, Tsugane S, & Takahashi K (2006) Decreased serum free testosterone in workers exposed to high levels of di-n-butyl phthalate (DBP) and di-2-ethylhexyl phthalate (DEHP): A cross-sectional study in China. *Environ Health Persp*, 114: 1643-1648.
- Parks L, Ostby J, Lambright C, Abbott B, Klinefelter G, Barlow N, & Gray LJ (2000) The plasticizer diethylhexyl phthalate induces malformations by decreasing fetal testosterone synthesis during sexual differentiation in the male rat. *Toxicological Sciences*, 58(2): 339-349.
- Peters J & Cook R (1973) Effects of phthalate esters on reproduction in rats. *Environ Health Perspect*, 65: 91-94.
- Pollack G, Buchanan J, Slaughter R, Kohli R, & Shen D (1985a) Circulating concentrations of di-(2-ethylhexyl) phthalate and its de-esterified phthalic acid products following plasticizer exposure in patients receiving hemodialysis. *Toxicol. Appl. Pharmacol.*, 79: 257-267
- Pollack G, Li R, Ermer J, & Shen D (1985b) Effects of route of administration and repetitive dosing on the disposition kinetics of di(2-ethylhexyl) phthalate and its mono-de-esterified metabolite in rats. *Toxicol. Appl. Pharmacol.* 79: 246-256.
- Pollack G, Shen D, & Dorr M (1989) Contribution of metabolites to the route- and timedependent hepatic effects of di-(2-ethylhexyl)phthalate in the rat. *J Pharmacol Exp Ther*, 248(1): 176-81.
- Poon R, Lecavalier P, Mueller R, Valli V, Procter B, & Chu I (1997) Subchronic Oral Toxicity of Di-N-Octyl Phthalate and Di(2-Ethylhexyl) Phthalate in the Rat. *Food & Chemical Toxicology*, 35(2): 225-239.
- Price C, Tyl RW, Marr M, Myers C, & Sadler B (1988) Reproduction and fertility evaluation of diethylhexyl phthalate (CAS No. 117-81-7) in CD-1 mice exposed during gestation, Cent. Life Sci. Toxicol., Research Triangle Inst., Research Triangle Park, NC, USA.
- Rais-Bahrami K, Nunez S, Revenis ME, Luban NL, & Short BL (2004) Follow-up study of adolescents exposed to di(2-ethylhexyl) phthalate (DEHP) as neonates on extracorporeal membrane oxygenation (ECMO) support. *Environ Health Perspect*, 112(13): 1339-1340.
- Rhodes C, Elcombe C, Batten P, Bratt H, Jackson S, Pratt I, & Orton T (1983) The disposition of ¹⁴C di-2-ethylhexylphthalate (DEHP) in the marmoset. *Dev. Toxicol. Environ. Sci.*, 11: 579-581.
- Rhodes C, Orton T, Pratt I, Batten P, Bratt H, Fackson S, & Elcombe C (1986) Comparative pharmacokinetics and subacute toxicity of di-(2-ethylhexyl) phthalate (DEHP) in rats and

- marmosets: extrapolation of effects in rodents to man. *Environ. Health Perspect.*, 65: 299-308
- Riddick J, Bunger WB, & Sakano TK (1986) *Organic solvents: physical properties and methods of purification-techniques of chemistry*. New York, Wiley-Interscience.
- RIVM (Rijksinstituut voor volksgezondheid en milieu) (1992) Toxicological investigation of di(2-ethylhexyl) phthalate in rats. The determination of a no-observed-effect-level, National Institute of Public Health and Environmental Protection to the Dutch Chief Inspectorate of Health Protection.
- Roth B, Herkenrath P, Lehmann HJ, Ohles HD, Homig HJ, Benz-Bohm G, Kreuder J, & Younossi-Hartenstein A (1988) Di-(2-ethylhexyl)-phthalate as plasticizer in PVC respiratory tubing systems: indications of hazardous effects on pulmonary function in mechanically ventilated, preterm infants. *Eur J Pediatr.* 147: 41-46.
- Rubin R & Chang J (1978) Effect of the intravenous administration of the solubilized plasticizer di(2-ethylhexyl) phthalate on the lung and on survival of transfused rats. *Toxicol. Appl. Pharmacol.*, 45: 230.
- Rutter H (1975) Three-week intravenous administration in dog of di(2-ethylhexyl)phthalate. Report for the National Heart and Lung Institute. NTIS PB-244-262.
- Salazar-Martinez E, Romano-Riquer P, Yanez-Marquez E, Longnecker M, & Hernandez-Avila M (2004) Anogenital distance in human male and female newborns: a descriptive, cross-sectional study. *Environmental Health*, 3: 3-18.
- Schilling K, Gembardt C, & Hellwig J (2001) Di-2-ethylhexyl phthalate - Two-generation reproduction toxicity study in Wistar rats, continuous dietary administration. Ludwigshafen, FRG., Experimental Toxicology and Ecology, BASF Aktiengesellschaft, D-67056.
- Schmezer P, Pool B, Klein R, Komitowski D, & Schmähl D (1988) Various short-term assays and two long-term studies with the plasticizer di-(2-ethylhexyl) phthalate in the Syrian golden hamster. *Carcinogenesis* 9: 37-43.
- Schmidt J, Garvin P, & Leestma J (1975) Effect of vehicle on the response to intravenous di-(2-ethylhexyl) phthalate (DEHP) in rats. *Toxicol. Appl. Pharmacol.*, 33: 169.
- Scott R, Dugard P, Ramsey J, & Rhodes C (1987) In vitro absorption of some o-phthalate diesters through human and rat skin. *Environ. Health Perspect.* 74: 223-227 Plus Errata.
- Shaffer CB, Carpenter CP, & Smyth HJ (1945) Acute and subacute toxicity of di(2-ethylhexyl) phthalate with note upon its metabolism. *J. Ind. Hyg. Toxicol.*, 27: 130-135.
- Shibko S & Blumenthal H (1973) Toxicology of phthalic acid esters used in food-packaging material. *Environmental Health Perspectives*, 4(3.): 131-137.
- Shiota K & Mima S (1985) Assessment of the teratogenicity of di(2-ethylhexyl) phthalate and mono (2-ethylhexyl) phthalate in mice. *Arch Toxicol*, 56:263-266.
- Shirota M, Saito Y, Imai K, Horiuchi S, Yoshimura S, Sato M, Nagao T, Ono H, & Katoh M (2005) Influence of di-(2-ethylhexyl)phthalate on fetal testicular development by oral administration to pregnant rats. *J Toxicol Sci*, 30: 175-94.
- Short RD, Robinson EC, Lington AW, & Chin AE (1987). Metabolic and peroxisome proliferation studies with di-(2-ethylhexyl) phthalate in rats and monkeys. *Toxicol. Ind. Health*, 3:185-195.
- Silva MJ, Reidy JA, Herbert AR, Preau JL, Needham LL, & Calafat AM (2004) Detection of phthalate metabolites in human amniotic fluid. *Bull. Environ. Contam. Toxicol.*, 72: 1226-1231.

- Singh A, Lawrence WH, & Autian J (1972) Teratogenicity of phthalate esters in rats. *J Pharm Sci*, 61: 51-55.
- Sjoberg P, Bondesson U, & Hammarlund M (1985a) Nonlinearities in the pharmacokinetics of di(2-ethylhexyl) phthalate and metabolites in male rats. *Archives of Toxicology*, 58(2): 72-77.
- Sjoberg P, Lindquist NG, Montin G, & Ploen L (1985b) Effects of repeated intravenous infusions of the plasticizer di(2-ethylhexyl) phthalate in young male rats. *Archives of Toxicology*, 58(2): 78-83.
- Sjoberg P, Lindqvist NG, & Ploen L (1986) Age-dependent response of the rat testes to di(2-ethylhexyl) phthalate. *Environ Health Perspect*, 65: 237-242.
- Staples CA, Peterson D, Parkerton T, & Adams W (1997) The environmental fate of phthalate esters. A literature review. *Chemosphere*, 35(4): 667-749.
- Swan S, Main K, Liu F, Stewart S, Kruse R, Calafat A, Mao C, Redmon J, Ternand C, Sullivan S, Teague J, & The-Study-for-Future-Families-Research-Team (2005) Decrease in anogenital distance among male infants with prenatal phthalate exposure. *Environ Health Perspect*, 113: 1056-1061.
- Takagi A, Sai K, Umemura T, Hasegawa R, & Kurokawa Y (1992) Hepatomegaly is an early biomarker for hepatocarcinogenesis induced by peroxisome proliferators. *J. Environ. Pathol. Toxicol. Oncol.*, 11: 145-149.
- Takeuchi S, Iida M, Kobayashi S, Jin K, Matsuda T, & Kojima H (2005) Differential effects of phthalate esters on transcriptional activities via human estrogen receptors α and β , and androgen receptor. *Toxicology*, 210: 223-233.
- Tenneco (1981) 28 day hepatotoxicity study in rats, Tenneco Chemicals.
- Thiess A & Fleig H (1978) Chromosomenuntersuchungen bei Mitarbeitern mit Exposition gegenüber Di-2-äthylhexylphthalat (DOP). *Zbl. Arbeitsmed.*, 28: 351-355.
- Thiess A, Frentzel-Beyme R, & Wieland R (1978a) Mortality study in workers exposed to di-2-ethylhexyl phthalate (DOP) (in German). Possibilities and limits of biological monitoring - Problems in occupational medicine of the industrial occupational health services, Frankfurt, Stuttgart, A.W. Gertner.
- Thiess A, Korte A, & Fleig H (1978b) Morbidity studies in workers exposed to di(2-ethylhexyl)phthalate (DEHP) (in German). Possibilities and limits of biological monitoring - Problems in occupational medicine of the industrial occupational health services, Frankfurt, Stuttgart, A.W. Gertner.
- Toda C, Okamoto Y, Ueda K, Hashizume K, Itoh K, & Kojima N (2004) Unequivocal estrogen receptor-binding affinity of phthalate esters featured with ring hydroxylation and proper alkyl chain size. *Arch Biochem Biophys*, 431: 16-21.
- Tomonari Y, Kurata Y, Kawasuso T, David R, Gans G, & Katoh M (2003) Testicular toxicity study of di(2-ethylhexyl) phthalate (DEHP) in juvenile common marmoset. *The Toxicologist*, 72: 385.
- Tomonari Y, Kurata Y, David RM, Gans G, Kawasuso T, & Katoh M (2006) Effect of di(2-ethylhexyl) phthalate (DEHP) on genital organs from juvenile common marmosets: I. Morphological and biochemical investigation in 65-week toxicity study. *J Toxicol Env Health*, 69: 1651-1672.
- Tomaszewski K, Agarwal D, & Melnick R (1986) In vitro steady-state levels of hydrogen peroxide after exposure of male F344 rats and female B6C3F1 mice to hepatic peroxisome proliferators. *Carcinogenesis*, 7: 1871-1876.

- Tugwood J, Aldridge T, Lambe K, MacDonald N, & Woodyatt N (1996) Peroxisome proliferator-activated receptors: Structures and function. *Ann N Y Acad Sci*, 804: 252-265.
- Tyl R, Price C, Marr M, & Kimmel C (1988) Developmental toxicity evaluation of dietary di(2-ethylhexyl) phthalate in Fischer 344 rats and CD-1 mice. *Fundam. Appl. Toxicol.*, 10: 395-412.
- Voss C, Zerban H, Bannasch P, & Berger MR (2005) Lifelong exposure to di-(2-ethylhexyl)-phthalate induces tumors in liver and testes of Sprague-Dawley rats. *Toxicology*, 206(3): 359-371.
- Ward J, Peters J, Perella C, & Gonzalez F (1998) Receptor and nonreceptor-mediated organ-specific toxicity of di(2-ethylhexyl)phthalate (DEHP) in peroxisome proliferator-activated receptor alpha-null mice. *Toxicol Pathol*, 26(2): 240-246.
- Watari N, Kanai M, Torizawa K, Mabuchi Y, & Hida Y (1978) Electron microscopical and cytochemical observations of the mouse liver following the administration of phthalate ester (DOP). *J. Clin. Electron Microscopy*, 11: 103-120.
- Wilson VS, Lambright C, Furr J, Ostby J, Wood C, Held G, & Gray LE Jr (2004) Phthalate ester-induced gubernacular lesions are associated with reduced *insl3* gene expression in the fetal rat testis. *Toxicology Letters*, 146: 207-15.
- Wolfe G & Layton K (2003) Diethylhexylphthalate: multigenerational reproductive assessment by continuous breeding when administered to Sprague-Dawley rats in the diet. *Govt Reports Announcements*, TherImmune Research Corp., Gaithersburg, MD. 12.
- Woodward K, Smith A, Mariscotti S, & Tomlinson N (1986) Review of the toxicity of the esters of o-phthalic acid (phthalate esters). London, Health and Safety Executive: 183.
- Woodyatt N, Lambe K, Myers K, Tugwood J, & Roberts R (1999) The peroxisome proliferator (PP) response element upstream of the human acyl CoA oxidase gene is inactive among a sample human population: significance for species differences in response to PPs. *Carcinogenesis*, 20(3): 369-372.
- Zacharewski TR, Meek MD, Clemons JH, Wu ZF, Fielden MR, & Matthews JB (1998) Examination of the in vitro and in vivo estrogenic activities of eight commercial phthalate esters. *Toxicol Science*, 46: 282-293.

Appendix 1 - Robust Study Summaries

A1 - Repeated dose toxicity

| | |
|----------------------|--|
| Test Substance | : DEHP |
| Type of Test | : Chronic study |
| Species | : Marmoset monkey, <i>Callithrix jacchus</i> , 90-115 days old. |
| Route of admin. | : Oral (gavage) |
| Study Duration | : 65 weeks |
| Frequency of treatm. | : Daily |
| Post exposure period | : None |
| Doses | : 100, 500 or 2500 mg/kg bw/d in corn oil |
| Control group | : Corn oil vehicle alone |
| NOAEL / NOEL | : 2500 mg/kg bw/d |
| LOAEL / LOEL | : Not identified |
| GLP& QA | : Not stated |
| Guidelines | : Not stated |
| Method | : Not a standard study |
| Result | : DEHP at concentrations up to 2500 mg/kg bw/d did not have any treatment-related effects on male organ weights and no microscopic changes were found in male gonads or secondary sex organs. Sperm head counts, zinc levels, glutathione levels and testicular enzyme activities were comparable between groups. Electron microscope examination revealed no treatment-related abnormalities in Leydig, Sertoli or spermatogenic cells. Histochemical examination of the testis after 3 β -hydroxysteroid dehydrogenase staining did not reveal any alterations in steroid synthesis in Leydig cells. In females, increased ovarian and uterine weights and elevated blood oestradiol levels were observed at 500 or 2500 mg/kg bw/d. These weight increases were associated with the presence of large corpus luteum, a common finding in older female marmosets. No abnormal histological changes were observed in ovaries or uteri in comparison to controls. No increases in hepatic peroxisomal enzyme activities were noted in treated groups. Isolated hepatic enzyme activities (P-450 contents, testosterone 6 β -hydroxylase and lauric acid ω -1 ω -hydroxylase activities) were increased in males and/or females at 500 or 2500 mg/kg bw/d but no consistent dose- related trends were observed. |
| Conclusion | : The results demonstrated that chronic oral exposure to DEHP did not affect male reproductive tract development in the marmoset monkey. |
| Reference | : Tomonari Y, Kurata Y, David RM, Gans G, Kawasuso T, & Katoh M (2006) Effect of di(2-ethylhexyl) phthalate (DEHP) on genital organs from juvenile common marmosets: |

I. Morphological and biochemical investigation in 65-week toxicity study. J. Toxicol. Env. Health 69: 1651-1672.

A2 - Developmental toxicity/teratogenicity

| | |
|----------------------|---|
| Test substance | : DEHP, BBP, DINP, DEP, DMP, DOTP |
| Species | : Sprague-Dawley female rats |
| Route of admin. | : Oral (gavage) |
| Exposure period | : GD 14 to PND 3 |
| Study Duration | : Not specified |
| Frequency of treatm. | : Daily |
| Doses | : 750 mg/kg bw/d |
| Control group | : Corn oil vehicle only |
| NOAEL maternal tox. | : 750 mg/kg bw/d |
| NOAEL teratogen. | : Not identified |
| Guidelines | : No information |
| GLP | : No information |
| Method | : No a standard test |
| Result | : None of the phthalates induced overt maternal toxicity or reduced litter sizes. However, DEHP treatment reduced maternal weight gain and DEHP and DINP caused decreases in pregnancy weight gain. Decreased pup weights were observed in DEHP and BBP groups. Male, but not female pups in both DEHP and BBP groups displayed shortened anogenital distance and reduced testes weights. As infants, males in the DEHP, BBP and DINP groups had female-like areolas/nipples and increased incidence of reproductive malformations. |
| Conclusion | : At this dose, DEHP, BBP and DINP altered sexual differentiation, whereas DOTP, DEP, and DMP were ineffective. |
| Reference | Gray LEJ, Ostby J, Furr J, Price M, Veeramachaneni D, & Parks L (2000) Perinatal exposure to the phthalates DEHP, BBP, and DINP, but not DEP, DMP, or DOTP, alters sexual differentiation of the male rat. Toxicological Sciences, 58: 350-365. |

A3 - Developmental toxicity/teratogenicity

| | |
|-------------------------|--|
| Test substance | : DEHP |
| Species | : Female Wistar rats |
| Route of admin. | : Oral (gavage) |
| Exposure period | : GD 6 to PND 21 |
| Study Duration | : No information |
| Frequency of treatment. | : Daily |
| Doses | : 0.015, 0.045, 0.135, 0.405, 1.215 mg kg bw/d (low doses); 5, 15, 45, 135 and 405 mg/kg bw/d (high doses) |

| | |
|---------------------|---|
| Control group | : Vehicle only (peanut oil) |
| NOAEL maternal tox. | : 135 mg/kg bw/d |
| NOAEL teratogen. | : 5 mg/kg bw/d |
| Guidelines | : No information |
| GLP | : No information |
| Method | : Not a standard study |
| Result | : In dams, liver and kidney weights were significantly increased at the highest dose level (405 mg/kg bw/d) No other signs of maternal toxicity were evident. Litter size, sex ratios, postimplantation losses and numbers of viable pups were also unaffected. In female offspring, a significant increase in liver weight was observed on PND1 (but not PND22) at 135 and 405 mg/kg bw/d. A significant delay in the age of vaginal opening was observed at 15 mg/kg bw/d and above. Anogenital distance and nipple development were unaffected. |
| Conclusion | : The data showed that DEHP induced delayed vaginal opening in females exposed to 15 mg/kg bw/d and above. |
| Reference | : Grande SW, Andrade AJ, Talsness CE, Grote K, & Chahoud I (2006) A Dose Response Study Following In Utero and Lactational Exposure to Di-(2-ethylhexyl) Phthalate (DEHP): Effects on Female Rat Reproductive Development. Toxicol. Sci. 91: 247-254. |

A4 - Developmental toxicity/teratogenicity

| | |
|-------------------------|---|
| Test substance | : DEHP |
| Species | : Female Wistar rats |
| Route of admin. | : Oral (gavage) |
| Exposure period | : GD 6 to PND 21 |
| Study Duration | : No information |
| Frequency of treatment. | : Daily |
| Doses | : 0.015, 0.045, 0.135, 0.405, 1.215 mg kg bw/d (low doses); 5, 15, 45, 135 and 405 mg/kg bw/d (high doses) |
| Control group | : Vehicle only (peanut oil) |
| NOAEL maternal tox. | : 135 mg/kg bw/d |
| NOAEL teratogen. | : 1.215 mg/kg/bw/d |
| Guidelines | : No information |
| GLP | : No information |
| Method | : Not a standard study |
| Result | : In dams, liver and kidney weights were significantly increased at the highest dose level (405 mg/kg bw/d) No other signs of maternal toxicity were evident. Litter sizes, sex ratios, postimplantation losses and numbers of viable pups were also unaffected. In offspring, a significant increase in liver weight was observed on PND 1 (but not PND22) at 135 and 405 mg/kg bw/d. Testes weights were significantly increased at 5, 15, |

45 and 135 mg/kg bw/d (but not 405 mg/kg bw/d) on PND 22. Nipple retention and reduced anogenital distance were seen with exposure to the highest dose (405 mg/kg bw/d). Delayed preputial separation was observed in animals exposed to 15 mg/kg bw/d and above. Histopathological examinations of testes on PND 1 and 22 showed changes at the two highest doses (135 and 405 mg/kg bw/d). On PND 1, bi- and multinucleated gonocytes were evident. On PND 22, signs of reduced germ cell differentiation in seminiferous tubules were observed.

- Conclusion : The data showed that DEHP acts as an anti-androgen in males at the highest dose level (405 mg/kg bw/d) but also induced subtle developmental effects at lower doses.
- Reference : Andrade AJM, Grande SW, Talsness CE, Grote K, Golombiewski A, Sterner-Kock A, & Chahoud I (2006) A dose response study following in utero and lactational exposure to di-(2-ethylhexyl) phthalate (DEHP): Effects on androgenic status, developmental landmarks and testicular histology in male offspring rats. *Toxicology* 225:64-74.

Appendix 2 – Effects of DEHP Following Repeated Oral, Inhalation and Parenteral Administration

(Adapted from FDA, 2002; ECB, 2006)

| Species, Study Duration, Route | Doses (mg/kg bw/d) | NOAEL (mg/kg bw/d) | LOAEL (mg/kg bw/d) | Effects at LOAEL | References |
|---|------------------------|--------------------|--------------------|---|-----------------------|
| ORAL | | | | | |
| <i>Short-term studies (up to 28-days exposure)</i> | | | | | |
| Rat, Sprague-Dawley Males 5 days (from day 6, 14-16, 21, 42, 86 of age) gavage, corn oil | 0, 10, 100, 1000, 2000 | 10 | 100 | <u>liver</u> : ↑ absw and relw from 100 mg/kg bw/d, ↑ pp, ↑ p.enz.act. ↓ TG, ↓ CHO | Dostal et al., 1987a* |
| Rat, Sprague-Dawley Females 5 days (2-6, 6-10, or 14-18 of lactation) gavage, corn oil | 0, 2000 | NE | 2000 | ↓ bw <u>liver</u> : ↑ relw all groups, ↑ p.enz.act. ↓ TG, ↓ CHO | Dostal et al., 1987b* |
| Rat, F344 5 males/group 1 week, diet | 0, 1.2% (0, 670) | NE | 670 | <u>liver</u> : ↑ absw and relw | Takagi et al., 1992* |
| Rat, F344 8 males 1 week, diet | 0, 2% (0, 1600) | NE | 1600 | ↓ CHO, ↓ TG ↑ absw and relw for <u>liver</u> and <u>kidney</u> no histological findings in liver, kidney, or testes | Exxon, 1982* |

| Species, Study Duration, Route | Doses (mg/kg bw/d) | NOAEL (mg/kg bw/d) | LOAEL (mg/kg bw/d) | Effects at LOAEL | References |
|---|--|--------------------|--------------------|---|--------------------------------------|
| Rat, Wistar 4 males/group 6 male controls 3, 10, or 21 days, diet | 0 or 2% (1650-1830) | NE | 1650-1830 | ↓ bw after 10-21 days <u>liver</u> : ↑ relw in all dosed males, ↑pp, ↑pSER, ↑p.enz.act., mitochondrial changes | Mann et al., 1984* |
| Rat, Alderley Park 20 rats/sex/group 3, 7, 14, 28 days, or 9 months, diet | 0, 50, 200, 1000 | NE | 50 | <u>liver</u> : ↑ wt from 50 mg/kg bw/d, ↑ pp, ↑ pSER, ↑ p.enz.act., mitochondrial changes (males) | CEFIC, 1982*; Mitchell et al., 1985* |
| Rat, Wistar 6 rats/sex/group 7 or 21 days, gavage | 0, 2500 | NE | 2500 | ↓ bwg (males) <u>liver</u> : ↑relw, no histological findings, ↑nb peroxisomes, ↑pSER | Mangham et al., 1981* |
| Rat, F344 4-5 rats/sex/group 1 or 3 weeks, diet | 0, 0.1, 0.6, 1.2% (0, 80, 480, 960) | NE | 80 | <u>liver</u> : ↑w, ↑ p.enz.act., ↓ TG | CMA, 1982* |
| Rat, F344 5 rats/sex/group 14 days, diet | 0, 6300, 12500, 25000, 50000, 100000 ppm (0, 630, 1250, 2500, 5000, 10000) | 630 | 1250 | <u>testes</u> : atrophy from 12500 ppm | NTP, 1982* |
| Rat, Alderley Park 10 rats/sex/group 14 days, gavage | 0, 2000 | NE | 2000 | ↓bwg (males) <u>liver</u> : ↑absw, ↑relw, ↑pp, ↑pSER, mitochondrial changes <u>kidney</u> : ↑weight (females), ↑pp <u>testes</u> : ↓weight, atrophy ↓CHO (males), ↓TG (males) | ICI, 1982*; Rhodes et al., 1986* |
| Rat, Sprague-Dawley 6 males/group 14 day gavage | 0, 1000 | NE | 1000 | <u>liver</u> : ↑relw, ↑p.enz.act. | Lake et al., 1984b* |

| Species, Study Duration, Route | Doses (mg/kg bw/d) | NOAEL (mg/kg bw/d) | LOAEL (mg/kg bw/d) | Effects at LOAEL | References |
|---|--|--------------------------|--------------------------|---|---------------------------------|
| Rat, Sprague-Dawley 5 males/group 14 days, gavage | 0, 25, 100, 250, 1000 | NE | 25 | <u>liver</u> : ↑p.enz.act. from 25 mg/kg bw/d | Lake et al., 1984a* |
| Rat, Wistar 6 males/group 2 or 4 weeks, diet | 0, 5, 18, 52, 182, 549 | 5 | 18 | <u>liver</u> : ↑nb peroxisomes from 18 mg/kg bw/d | RIVM, 1992* |
| Rat, Wistar 5 males/group 14 days, gavage | 0, 250, 500, 1000, 2000 | 250 | 500 | <u>liver</u> : ↑relw from 500 mg/kg bw/d | Khaliq & Srivastava, 1993* |
| Rat, Wistar 5-6 males/group 16 days, diet | 0, 0.01, 0.025, 0.05, 0.1, 0.5, 1.0% (0, 8, 22, 42, 88, 500, 900 | 42 | 88 | <u>liver</u> : ↑relw at 88 mg/kg bw/d | Fukuhara & Takabatake, 1977* |
| Rat, F344 4-5 males/group 3 weeks, diet | 0, 2% | NE | NE | <u>liver</u> : ↑relw, ↑p.enz.act. hypolipidemia | Moody & Reddy, 1978* |
| Rat, Sprague-Dawley 4 males 3 weeks, diet | 0, 2% (0, 900) | NE | 900 | ↓bw and bwg <u>liver</u> : ↑absw and relw, ↑nb peroxisomes, ↑pSER, ↑p.enz.act. <u>kidney</u> : ↑absw and relw ↑CHO and TG (trend only) | General Motors, 1982a,b* |
| Rat, F344 5 rats/sex/group 21 days, diet | 0, 0.01, 0.1, 0.6, 1.2, 2.5% (0, 11, 105, 667, 1224, 2101 [M]; 0, 12, 109, 643, 1197, or 1892 [F]) | NE | 11 | ↑TG at 0.01% (males) | CMA, 1984*; Barber et al., 1987 |

| Species, Study Duration, Route | Doses (mg/kg bw/d) | NOAEL (mg/kg bw/d) | LOAEL (mg/kg bw/d) | Effects at LOAEL | References |
|---|--|--------------------------|--------------------------|---|---------------------------|
| Rat, F344, 5 males/group 21 days, diet | 0, 100, 1000, 6000, 12000, 25000 ppm (0, 11, 105, 667, 1223, 2100) | 11 | 105 | liver: ↑p.enz.act. from 1000 ppm | Short et al., 1987* |
| Rat, Wistar 3 males/group 2-4 weeks, diet | 0, 2% (4 w) or 2 w, 2% +2 w control diet | NE | NE | <u>liver</u> : ↑ wt during treatment period, ↓ during withdrawal period; ↑ p.enz.act. during treatment, ↓ during withdrawal | Miyazawa et al., 1980* |
| Rat, F344 5 rats/sex/group 28 days, diet | 0, 0.2, 0.67, 2.0% (M: 0, 150, 504, 1563); (F: 0, 147, 490, 1416) | NE | 150 | <u>liver</u> : ↑absw and relw from 0.2%, ↑p.enz.act., ↓ total lipids | Nuodex, 1981c* |
| Rat, F344 5 males/group 28 days, gavage | 0, 1000 | NE | 1000 | <u>liver</u> : ↑absw and relw | Tenneco, 1981* |
| Rat, F344 5 rats/sex/group 28 days, diet | 0, 0.67% (0, 350) | NE | 350 | <u>liver</u> : ↑relw, ↑nb peroxisomes, and ↑p.enz.act. at 0.67% | Hodgson, 1987* |
| Rat, F344 5 rats/sex/group 21 days, gavage | 0 700 | NE | 700 | <u>liver</u> : ↑relw, ↑nb peroxisomes, and ↑p.enz.act. at 700 mg/kg bw/d | Hodgson, 1987* |
| Rat, F344 5 males/group 10 males/control group 28 days, diet | 0, 0.02, 0.05, 0.1, 0.5, 1.0, 2.5% (0, 24, 52, 115, 559, 1093, 2496) | NE | 24 | <u>liver</u> : ↑relw from 0.02% | BIBRA, 1990* |

| Species, Study Duration, Route | Doses (mg/kg bw/d) | NOAEL (mg/kg bw/d) | LOAEL (mg/kg bw/d) | Effects at LOAEL | References |
|---|---|--------------------|--------------------|--|---------------------------|
| Mouse, B6C3F1 10 males/group 5 days, gavage | 0, 1879, 2844, 4304, 6514, 9860 | NE | 1879 | <u>liver</u> : enlarged with a slight dose-response trend from 1879 mg/kg bw/d | Nuodex, 1981b* |
| Mouse, CD-1 10 females/group 8 days, gavage, corn oil | 0, 6000, 7690, 9860 | NE | 6000 | clinical signs of toxicity from 6000 mg/kg bw/d | Hazleton, 1983* |
| Mouse, B6C3F1 5 mice/sex/group 14 days, diet | 0, 6300, 12500, 25000, 50000, 100000 ppm (0, 630, 1250, 2500, 5000, 10000) | 1250 | 2500 | ↓bw, ↓bwg from 25000 ppm (males) | NTP, 1982* |
| Mouse, B6C3F1 10 mice/sex/group 4 weeks, diet | 0, 1000, 5000, 10000, 25000 ppm (M: 0, 250, 1210, 2580, or 6990); (F: 0, 270, 1430, 2890, 7900) | 250 | 1210 | ↓bw and bwg from 5000 ppm (males) <u>liver</u> : ↑absw and relw from 5000 ppm <u>kidney</u> : ↓absw from 5000 ppm (males), inflammation from 5000 ppm | Eastman Kodak, 1992a* |
| Rat, F344 5 males/group Mouse, B6C3F1 5 females/group 14 days, gavage | 0, 2000 | NE | 2000 | <u>palmitoyl CoA oxidase</u> : 9-fold and 21-fold ↑ in rats and mice, respectively. <u>catalase</u> : 2-fold and 3-fold ↑ in rats and mice, respectively. <u>glutathione peroxidase</u> : ↓ 50% and 35% of the control in rats and mice respectively. | Tomaszewski et al., 1986* |
| <i>Subchronic Studies (>28-days exposure <chronic exposure)</i> | | | | | |
| Rat, Sprague-Dawley 10 rats/sex/group 13 weeks, diet | 0, 5, 50, 500, 5000 ppm (M: 0, 0.4, 3.7, 37.6, 375.2); (F: 0, 0.4, 4.2, 42.2, 419.3) | 3.7 | 37.6 | <u>testes</u> : mild to moderate Sertoli cell vacuolation from 500 ppm | Poon et al., 1997 |

| Species, Study Duration, Route | Doses (mg/kg bw/d) | NOAEL (mg/kg bw/d) | LOAEL (mg/kg bw/d) | Effects at LOAEL | References |
|--|---|--------------------------|-------------------------------|---|--|
| Rat, F344 10 rats/sex/group 13 weeks, diet | 0, 1600, 3100, 6300, 12500, 25000 ppm (0, 80, 160, 320, 630, 1250) | 320 | 630 | ↓bwg at 25000 ppm <u>testes</u> : atrophy from 12500 ppm | NTP, 1982* |
| Rat, F344 10 rats/sex/group 13 weeks, diet | 0, 1000, 4000, 12500, 25000 ppm (M: 0, 63, 261, 859, 1724); (F: 0, 37, 302, 918, 1858) | NE | 37 (females) 63 (males) | <u>liver</u> : ↑absw and relw from 1000 ppm | Eastman Kodak, 1992b* |
| Mouse, B6C3F1 10 mice/sex/group 13 weeks, diet | 0, 800, 1600, 3100, 6300, 12500 ppm (0, 100, 200, 400, 800, 1600) | NE | 100 | ↓bwg from 800 ppm (females) | NTP, 1982* |
| <i>Chronic Toxicity Studies (>10% of the test animals lifespan)</i> | | | | | |
| Rat, Sprague-Dawley 15 rats/sex/group 17 weeks, diet; | 0, 0.2, 1.0, or 2.0% (M: 0, 143, 737, 1440); (F: 0, 154, 797, 1414) | NE | 143 | <u>liver</u> : ↑absw and relw from 0.2%, no histological findings | Gray et al., 1977* |
| Rat, F344 5-10 males/group 1, 2, 4, 8, 18, 39, 77, 151, or 365 days, diet | 0 or 1.2% (0, 600) | NE | 600 | ↑p.enz.act. | Conway et al., 1989* |
| Rat, Sprague-Dawley 520 males in total 102 weeks, diet | 0, 0.02, 0.2, 2.0% (0, 7, 70, or 700) | NE | 7 | ↓bw from 0.2% <u>liver</u> : ↑p.enz.act. from 0.02%, no tumours <u>testes</u> : atrophy and inhibition of spermatogenesis from 0.02% | Ganning et al., 1987*; Ganning et al., 1990* |
| Rat, F344 50 rats/sex/group 103 weeks, diet | 0, 6000, 12000 ppm (M: 0, 322, 674); (F: 0, 394, 774) | NE | 322 | <u>liver</u> : neoplastic lesions from 6000 ppm; <u>testes</u> : seminiferous tubular degeneration at 6000 ppm | NTP, 1982* |

| Species, Study Duration, Route | Doses (mg/kg bw/d) | NOAEL (mg/kg bw/d) | LOAEL (mg/kg bw/d) | Effects at LOAEL | References |
|--|--|----------------------|--------------------|---|-----------------------|
| Rat, F344 70-85/sex/group 55/sex/recovery group 104 weeks, diet | 0, 100, 500, 2500, 12500 ppm (M: 0, 5.8, 28.9, 146.6, 789.0); (F: 0, 7.3, 36.1, 181.7, 938.5) or 12500 ppm for 78 weeks, followed by a recovery period of 26 weeks | 28.9 [M] 36.1 [F] | 146.6-181.7 | <u>liver</u> : ↑ wt (males) and peroxisome proliferation at 2500 ppm; <u>kidney</u> : ↑ weight from 2500 ppm testes: ↓ wt, ↑ incidence and severity of bilateral aspermatogenesis; ↓ incidence of interstitial cell neoplasms | Moore, 1996* |
| Rat, Sprague-Dawley 5 males/group 8 males/control group 2 years, diet | 0, 2% (0, 1000) | NE | 1000 | <u>liver</u> : ↑relw, ↑ nb mitochondria, ↑nb peroxisome ↑p.enz.act. and lipid peroxidation | Lake et al., 1987* |
| Mouse, B6C3F1 50 mice/sex/group 103 weeks, diet | 0, 3000, 6000 ppm (M: 0, 672, 1325); (F: 0, 799, 1821) | 672-799 | 1325-1821 | ↓bw at 6000 ppm (females) <u>liver</u> : hepatocellular neoplastic lesions <u>kidney</u> : inflammation at 6000 ppm (males) <u>testes</u> : seminiferous tubular degeneration and testicular atrophy at 6000 ppm | NTP, 1982* |
| Mouse, B6C3F1 70-85/sex/group; 55/sex/recovery group 104 weeks, diet | 0, 100, 500, 1500, 6000 ppm (M: 0, 19.2, 98.5, 292.2, 1266.1); (F: 0, 23.8, 116.8, 354.2, 1458.2) or 6000 ppm followed by a recovery period of 26 weeks | 19.2 [M] 23.8 [F] | 98.5-116.8 | <u>liver</u> : peroxisome proliferation and ↑ weight (males) from 500 ppm | Moore, 1997* |
| Rat, males One year, by gavage, three times weekly | 0, 0.9, 0.9 leachate from toluene extraction | NE | 0.9 | <u>kidneys</u> : statistically significant ↑ incidence of focal cystic changes; ↓ creatinine clearance | Crocker et al., 1988* |
| Monkey, Marmoset 4/sex/group 13 weeks, gavage | 0, 100, 500 2500 | 2500 | NE | No effects | Kurata et al., 1998* |

| Species, Study Duration, Route | Doses (mg/kg bw/d) | NOAEL (mg/kg bw/d) | LOAEL (mg/kg bw/d) | Effects at LOAEL | References |
|--|--------------------------------------|--------------------------|--------------------------|---|--|
| Monkey, Marmoset 9 M, 6 F 65 weeks, daily gavage | 0, 100, 500 2500 | 2500 | NE | No effects on liver and testes wt, accessory male reproductive organs; no testicular lesions, no differences in sperm counts. | Mitsubishi- Chemical-Safety- Institute, 2003*; McKee et al., 2004 |
| Monkey, Marmoset 5-6/sex/group 65 weeks, gavage | 0, 100, 500 2500 | 2500 | NE | No effects on body weight or liver weight. No changes in hepatic peroxisomal enzyme activities. | Tomonari et al., 2006 |
| INHALATION | | | | | |
| Rat, Wistar 10/group 4 weeks | 0, 0, 10, 50, 1000 mg/m ³ | 50 | 1000 | ↑ lung wt | BASF, 1990*; Klimisch* et al., 1992 |
| Rat, Wistar 4/group 4-8 weeks | 0, 5, 25 mg/m ³ | 5 | 25 | ↓ seminal vesicle wt | Kurahashi et al., 2005 |
| Hamster, Syrian golden 23 months | 15 ug/m ³ | 15 | NE | No effects | Schmezer et al., 1988* |
| PARENTERAL | | | | | |
| Rat, Sprague-Dawley 5-6/group 12 days, IV | 0, 2.5, 25, 250 | 25 | 250 | <u>Testes</u> : Sertoli cell change at 250 | Sjoberg et al., 1985b |
| Rat, strain not specified 12/group 18 days, IV | 0, 30.8, 91.7, 164.8 | 92 | 165 | ↓ bw, ↑ liver wt at 165 | Greener et al., 1987* |

| Species, Study Duration, Route | Doses (mg/kg bw/d) | NOAEL (mg/kg bw/d) | LOAEL (mg/kg bw/d) | Effects at LOAEL | References |
|---|--|-----------------------------------|-----------------------------------|--|--------------------------------------|
| Rat, strain not specified 7/group 18 days, IV | 0, 62 | 62 | NE | No effect | Baxter Healthcare Corporation, 2000* |
| Rabbit, strain not specified 5/group 28 days, IV | 0, 62 | 62 | NE | No effect | Baxter Healthcare Corporation*, 2000 |
| Rat, Sprague-Dawley 7/group 21 days, IV | 0, 60, 300, 600 | 60 | 300 | Testicular atrophy, ↓ testes wt, ↑ liver wt. | Cammack et al., 2003 |
| Mouse, Swiss Webster 6 males/group 5 days, IP or every other day for 20 days | 0, 50, 100 | 100 | NE | No effects | Curto & Thomas, 1982* |
| Rat, Sprague-Dawley Mouse, Swiss Webster 6 males/group every other day for 20 days, IP | 0, 50, 100 | 50 | 100 | ↓ gonadal zinc at 100 | Curto & Thomas, 1982* |
| Monkey, Rhesus 3 males/group 6-12 month, IV | 0, 8 (plasma stored at 4°C), 27 (plasma stored at 20°C), 32 (platelet poor plasma stored at 22°C) | 32 | NE | Probable non-treatment related effects due to disease in colony | Jacobson et al., 1977* |
| Rat, Uremic 14 days, IP | 2000 | 2000 | NE | No adverse effects | Leber & Uviss, 1979* |

| Species, Study Duration, Route | Doses (mg/kg bw/d) | NOAEL (mg/kg bw/d) | LOAEL (mg/kg bw/d) | Effects at LOAEL | References |
|--|-----------------------|--------------------------|--------------------------|--|-------------------------|
| Rat 56 doses over 19 weeks, IP | 500 | | 210.5 | Hepatomegaly, ↑ MFO activity, ↓ GST activity | Leber & Uviss, 1979* |
| Rat 7 days, IP | 3906 | NE | 3906 | Hepatomegaly | Pollack et al., 1989* |
| Rat Every other day for 12 days, IP | Up to 7.5 | 3.8 | NE | No adverse effects, ↓ liver vitamin A at 0.75 and above | Nair et al., 1998* |
| Dog 6 doses/week for 6 weeks, IV | NA | 1 | NE | No adverse effects | Rutter, 1975* |

↓ / ↑ = decreased/increased; absw: absolute weight; relw: relative weight; bw: body weight; bwg: body weight gain; CHO / TG: cholesterol/triglyceride; M: male; F: female; NA: not available; nb: number; NE: not established; p.enz.act.: peroxisomal enzyme activity or activities; pp: peroxisome proliferation; pSER: proliferation of smooth endoplasmic reticulum.

Appendix 3 – Key Reproduction Studies with DEHP in Laboratory Animals

(Adapted from FDA, 2002; ECB, 2006)

| Study Design/ Species | Route | Doses (mg/kg bw/d) | NOAEL (mg/kg bw/d) | LOAEL (mg/kg bw/d) & Endpoint | References |
|---|--------|--|--|--|--------------------------|
| ORAL | | | | | |
| <i>Two-generation studies</i> | | | | | |
| 17 males/group | | 1000, 7500, 10000 ppm (F0/F1/F2: 0.1, 0.5-0.8, 1.4-2.4, 4.8-7.9, 14-23, 46-77, 359-592, 543-775) | <u>Fert</u> : 46 <u>Devp</u> : 4.8 | <u>Fert</u> : 592, ↓ nb live pups (F1); <u>Devp</u> : 14, testes, epididymis atrophy (F1,2) | 2003) |
| Rat, Wistar; 25/group | Diet | 0, 1000, 3000, 9000 ppm (0, 113, 340, 1088) | <u>Mat</u> : 340 <u>Fert</u> : NE <u>Devp</u> : NE | <u>Mat</u> : 1088, ↓ bw & food consumption <u>Fert</u> : 113, minimal testes atrophy (F2); <u>Devp</u> : 113, testes atrophy (described above) | (Schilling et al., 2001) |
| <i>Repeat dose studies</i> | | | | | |
| Mouse, CD-1 11-week-old 20 pairs of mice 98 days | Diet | 0, 0.01, 0.1, 0.3 % (0, 14, 140, 425) | <u>Sys</u> : 140 <u>Fert</u> : 14 | <u>Sys</u> : 425 <u>Fert</u> : 140, reduced fertility; ↓ Live pups per litter | (Lamb et al., 1987) |
| Rat, Long-Evans 10/group 70 or 100 days | Gavage | 0, 10, 100 | <u>Sys</u> : NE <u>Fert</u> : NE | <u>Sys</u> : NE <u>Fert</u> : 10, ↑ serum LH and testosterone, ↑ nb Leydig cells | (Akingbemi et al., 2004) |

| Study Design/ Species | Route | Doses (mg/kg bw/d) | NOAEL (mg/kg bw/d) | LOAEL (mg/kg bw/d) & Endpoint | References |
|---|--------|---|---|---|--|
| Rat, F344 24 males/group 60 days | Diet | 0, 320, 1250, 5000, 20000 ppm (0, 18, 69, 284, or 1156 mg/kg bw/d) | <u>Sys</u> : 69 <u>Fert</u> : 69 | <u>Sys</u> : 284, ↓ bw <u>Fert</u> : 284, ↓ testis, epididymis, and prostate wt | (Agarwal et al., 1986a*; Agarwal et al., 1986b*) |
| Rat, F344 50-80/group 104 weeks | Diet | 0, 100, 500, 2500, 12500 ppm (0, 5.8, 29, 147, 789) | <u>Sys</u> : 29 <u>Fert</u> : 5.8 | <u>Sys</u> : 147, ↑ liver & kidney wt (M) <u>Fert</u> : 29, ↑ aspermatogenesis (age related ?) | (David et al., 2000a) |
| Monkey, Marmosets 4/sex/group 12–15 months (post pubertal) 13 weeks | Gavage | 0, 100, 500, 2500 | <u>Sys</u> : 2500 <u>Fert</u> : 2500 | <u>Sys</u> : no effect <u>Fert</u> : no effect | (Kurata et al., 1998*) |
| Rat, Sprague-Dawley 4–6-week-old 10/sex/group 90 days | Diet | 0, 5, 50, 500, 5000 ppm (0, 0.4, 3.7, 37.6, 375.2 [M]) | <u>Sys</u> : 37.6 <u>Fert</u> : 3.7 | <u>Sys</u> : 375.2, ↑ liver & kidney wt <u>Fert</u> : 37.6, Mild Sertoli cell vacuolation | (Poon et al., 1997) |
| Rat, Long-Evans PND 21–34, 35–48, or 21–48, PND 62–89. 10/group 14 or 28 days | Gavage | 0, 1, 10, 100, 200 | <u>Sys</u> : 200 <u>Fert</u> : 1 | <u>Sys</u> : no effect on bw <u>Fert</u> : 10, ↓ 17α-hydroxylase intestis, altered ex vivo Leydig cell testosterone synthesis | (Akingbemi et al., 2001) |
| Rat, Sprague Dawley 1, 2, 3, 6, 12 weeks of age 7-10/group, 5 days | Gavage | 0, 100, 200, 500, 1000 | <u>Sys</u> : NE <u>Fert</u> : 200 | <u>Sys</u> : 100: ↑ abs & rel liver wt <u>Fert</u> : 500, ↓ Sertoli cell nuclei in 1 wk old rats, loss of spermatocytes in 2- & 3-week old rats | (Dostal et al., 1988) |

| Study Design/ Species | Route | Doses (mg/kg bw/d) | NOAEL (mg/kg bw/d) | LOAEL (mg/kg bw/d) & Endpoint | References |
|---|--------|---|---|---|---|
| Rat, Sprague Dawley 25, 40, 60 day old 6/group 14 days | Diet | 0, 1000, 1700 | <u>Sys</u> : 1000 <u>Fert</u> : 1000 (25, 40 day old) | <u>Sys</u> : 1700, ↓ bwg <u>Fert</u> : 1700, ↓ testicular wt; testicular damage in 25- & 40-day-old rats given. No changes in 60-day-old rats | (Sjoberg et al., 1986) |
| Monkey, Marmosets 90–115 days of age 65 weeks | Gavage | 0, 100, 500, 2500 | <u>Sys</u> : 2500 <u>Fert</u> : 2500 | <u>Sys</u> : NE <u>Fert</u> : NE | (Mitsubishi- Chemical-Safety- Institute, 2003*) |
| <i>Prenatal Developmental Toxicity Studies</i> | | | | | |
| Mouse, 1-CR 30-31 F/group GD 0-20 | Diet | 0, 0.025, 0.05, 0.10, or 0.15% (0, 44, 91, 190.6, 292.5) | <u>Mat</u> : 91 <u>Devp</u> : 44 | <u>Mat</u> : 190.6, ↓ maternal bwg, ↓ uterine wt, <u>Devp</u> : 91, ↓ foetal bw and nb live foetuses/litter; ↑ nb & % of resorptions, late foetal deaths, dead & malformed foetuses, & % malformed foetuses/litter, visceral malformations & skeletal defects | (NTIS, 1984*; Tyl et al., 1988) |
| Mouse, CD-1 15 F/group GD 6-15 | Gavage | 0, 40, 200, 1000 | <u>Mat</u> : 200 <u>Devp</u> : 40 | <u>Mat</u> : 1000, ↓ bwg <u>Devp</u> : 200, foetotoxic effects, ↓ nb viable foetuses | (Huntingdon, 1997*) |
| Mouse, CD-1 28–29/group GD 0-17 | Diet | 0, 0.01, 0.025, 0.05% (0, 19, 48, 95) | <u>Mat</u> : 95 <u>Devp</u> : 48 | <u>Mat</u> : no effect <u>Devp</u> : 95, ↑ prenatal mortality, ↓ litter size | (Price et al., 1988*) |
| Rat, F344/CrlBr 34-25 F/group GD 0-20 | Diet | 0, 0.5, 1.0, 1.5, or 2% (0, 357, 666, 856, 1055) | <u>Mat</u> : 357 <u>Devp</u> : 357 | <u>Mat</u> : 666, ↓ maternal food intake, ↓ maternal bwg <u>Devp</u> : 666, ↓ foetal wt | (NTIS, 1984*; Tyl et al., 1988) |
| Rat, F344 GD 0-20 | Diet | 0, 0.25, 0.5, 1.0% (0, 164, 313, 573) | <u>Mat</u> : 313 <u>Devp</u> : 164 | <u>Mat</u> : 573, ↓ maternal bwg <u>Devp</u> : 313, ↓ litter size, ↓ pup bw (pup wt in high- dose group recovered by PND4). | (Price et al., 1988*) |

| Study Design/ Species | Route | Doses (mg/kg bw/d) | NOAEL (mg/kg bw/d) | LOAEL (mg/kg bw/d) & Endpoint | References |
|--|--------|-----------------------|---------------------------------------|---|-------------------------------------|
| Rat, Wistar 9-10 F/group GD 6-15 | Gavage | 0, 40, 200, 1000 | <u>Mat</u> : 200 <u>Devp</u> : 200 | <u>Mat</u> : 1000, ↓ maternal bw, ↑ maternal relative kidney and liver wt <u>Devp</u> : 1000, ↓ nb live foetuses/dam, ↓ foetal bw, ↑ nb malformed foetuses/dam | (BASF, 1995*; Hellwig et al., 1997) |
| Rat, Sprague-Dawley 3-9/group GD 7-18 Examined: GD 20, 5 or 10 weeks (Exp 2) | Gavage | 0, 125, 250, 500 | <u>Mat</u> : 500 <u>Devp</u> : 250 | <u>Mat</u> : NE <u>Devp</u> : 500, Leydig cell hyperplasia | (Shirota et al., 2005) |
| Rat, Wistar 8/group GD 7-21 | Gavage | 0, 10, 30, 100, 300 | <u>Mat</u> : NR <u>Devp</u> : 30 | <u>Mat</u> : NR <u>Devp</u> : 100, ↑ testicular path | (Borch et al., 2006) |
| Rat, Sprague-Dawley 6 dams/group GD 7-18 Evaluated: GD 12, 14, 16, 18, 20, 7 weeks | Gavage | 0, 500, 1000 | <u>Mat</u> : 500 <u>Devp</u> : 250 | <u>Mat</u> : 1000, ↓ dam bw <u>Devp</u> : 500, small foetal testes, hyperplasia of interstitial cells | (Shirota et al., 2005) |
| Rat, Long-Evans 7/group GD 12-21 Evaluated: PND 21, 35, or 90 | Gavage | 0, 100 | <u>Mat</u> : 100 <u>Devp</u> : NE | <u>Mat</u> : NE, no effects on dam bw or bwg <u>Devp</u> : 100, ↓ Serum testosterone and LH at PND 21- and 35 but not at 90 days | (Akingbemi et al., 2001) |
| Rat, Wistar 18/group GD 7-21 | Gavage | 0, 300, 750 | <u>Mat</u> : 750 <u>Devp</u> : NE | <u>Mat</u> : NE <u>Devp</u> : 750, testicular histological effects | (Borch et al., 2005) |

| Study Design/ Species | Route | Doses (mg/kg bw/d) | NOAEL (mg/kg bw/d) | LOAEL (mg/kg bw/d) & Endpoint | References |
|--|----------------------------|-----------------------|--|---|--------------------------|
| <i>Developmental/Postnatal Toxicity Studies</i> | | | | | |
| Rat, Sprague-Dawley 11/group GD 14-PND 2 | Gavage | 0, 750 | <u>Mat</u> : NE <u>Fert</u> : NE <u>Devp</u> : NE | <u>Mat</u> : 750, ↓ mat wt gain <u>Fert</u> : NE <u>Devp</u> : 750, ↓ testes wt at GD 20, PND2, ↓ bw at PND2 not GD20, ↓ testosterone and AGD (abs and rel) from GD17, ↑ Leydig cell hyperplasia and multinucleated gonocytes observed in testes. | (Parks et al., 2000) |
| Rat, Sprague-Dawley 5-19/group GD 14-PND 3 | Gavage | 0, 750 | <u>Mat</u> : 750 <u>Fert</u> : 750 <u>Devp</u> : NE | <u>Mat</u> : NE <u>Fert</u> : NE. <u>Devp</u> : 750, ↓ maternal wt gain, ↓ pup wt in male pups, ↓ AGD and ↓ testis wt, retention of female-like areolas/nipples, ↑ incidence of reproductive malformations | (Gray et al., 2000*) |
| Rat, Wistar 20/group GD 7-PND 17 | Gavage | 0, 300, 750 | <u>Mat</u> : NE <u>Fert</u> : NE <u>Devp</u> : NE | <u>Mat</u> : NE <u>Fert</u> : NE <u>Devp</u> : 300, ↓ AGD; abnormal testis histology | (Jarfelt et al., 2005*) |
| Rat, Sprague-Dawley 5-8 /group GD 3-PND 21 | Gavage | 0, 375, 750, 1500 | <u>Mat</u> : 375 <u>Fert</u> : 750 <u>Devp</u> : 375 | <u>Mat</u> : 750, ↓ wt gain <u>Fert</u> : 1500, ↓ litter size <u>Devp</u> : 750, ↓ pup survival, ↓ AGD | (Moore et al., 2001*) |
| Rat, Wistar 10/group GD 1-PND 21 | Gavage | 0, 20, 100, 500 | <u>Mat</u> : 500 <u>Fert</u> : 100 <u>Devp</u> : 100 | <u>Mat</u> : NE <u>Fert</u> : 500, ↓ litter size, <u>Devp</u> : 500, ↓ prostate wt, ↓ sperm nb & production | (Dalsenter et al., 2006) |
| Rat, Long Evans 12/group GD 1-PND 21 | Oral, drinking water | 0, 3.0-3.5, 30-35 | <u>Mat</u> : 30-35 <u>Fert</u> : NE <u>Devp</u> : NE | <u>Mat</u> : NE <u>Fert</u> : 3.0-3.5, ↓ testicular wt with only a few elongated spermatids in tubules at the low dose level <u>Devp</u> : 3.0-3.5, ↓ pup kidney wt | (Arcadi et al., 1998*) |

| Study design/Species | Route | Doses (mg/kg bw/d) | NOAEL (mg/kg bw/d) | LOAEL (mg/kg bw/d) & Endpoint | References |
|--|-----------|---|--|---|-----------------------------|
| INHALATION | | | | | |
| Rat, Wistar 25 F/ group GD 6-15 | Head-nose | 0, 0.01, 0.05, or 0.3 mg/litre (0, 10, 50, or 300 mg/m ³) 6h/d | <u>Mat</u> : 300 <u>Fert</u> : 300 <u>Devp</u> : 300 | <u>Mat</u> : NE <u>Fert</u> : NE <u>Devp</u> : NE (↓ nb live fetuses at 50 mg/m ³ but not 300 mg/m ³ ; ↑ % of resorptions at 50 mg/m ³ but not 300 mg/m ³) | (Merkle et al., 1988*) |
| PARENTERAL | | | | | |
| Rat GD 6-15. | IV | 0, 1.3-1.4, 4.7-5.3 | <u>Mat</u> : 4.7-5.3 <u>Fert</u> : 4.7-5.3 <u>Devp</u> : 4.7-5.3 | <u>Mat</u> : NE <u>Fert</u> : NE <u>Devp</u> : NE | (Lewandowski et al., 1980*) |
| Rat, Sprague-Dawley 5/group GD 5, 10, and 15 | IP | 0, 4930 and 9860 | <u>Mat</u> : NE <u>Fert</u> : NE <u>Devp</u> : NE | <u>Mat</u> : <u>Fert</u> : 4930, ↓ implantations <u>Devp</u> : 4930, ↓ foetal wt | (Singh et al., 1972*) |
| Rat, Sprague-Dawley 5/group GD3, 6, and 9 Examined at weaning | IP | 0, 1972, 3944□ | <u>Mat</u> : NE <u>Fert</u> : NE <u>Devp</u> : NE | <u>Mat</u> : 1972, ↑ dam deaths <u>Fert</u> : 1972, ↓ implantations <u>Devp</u> : 1972, ↓ nb of weaned pups | (Peters & Cook, 1973*) |

M: male; F: female; AGD: anogenital distance; bw: body weight; bwg: body weight gain; nb: number; NE: not established; NR: not reported; Mat: maternal; Fert: fertility; Devp: development; wt: weight